

List of TSQM publications by topic

Source: PubMed

Search terms: "TSQM" AND "Endpoint"

- **TSQM as primary endpoint:**

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R. **Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.** *Mult Scler Relat Disord.* 2019 Jun;31:157-164. doi: 10.1016/j.msard.2019.03.022. Epub 2019 Mar 30. PMID: 31005729.

Centonze D, Fantozzi R, Buttari F, Grimaldi LME, Totaro R, Corea F, Marrosu MG, Confalonieri P, Cottone S, Trojano M, Zipoli V. **Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).** *Front Neurol.* 2021 Apr 22;12:637615. doi: 10.3389/fneur.2021.637615. PMID: 33967938; PMCID: PMC8101263.

Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E. **Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE).** *PLoS One.* 2021 Nov 15;16(11):e0259389. doi: 10.1371/journal.pone.0259389. PMID: 34780502; PMCID: PMC8592402.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R; Teri-PRO Trial Group. **Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.** *Mult Scler Relat Disord.* 2017 Oct;17:107-115. doi: 10.1016/j.msard.2017.07.006. Epub 2017 Jul 6. PMID: 29055438.

Forst T, Koch C, Dworak M. **Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study.** *Curr Med Res Opin.* 2015 Jun;31(6):1079-84. doi: 10.1185/03007995.2015.1039936. Epub 2015 May 20. PMID: 25867771.

Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K. **Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.** *BMC Neurol.* 2014 Nov 26;14:220. doi: 10.1186/s12883-014-0220-1. PMID: 25424122; PMCID: PMC4253981.

- **TSQM as secondary endpoint:**

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. **Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.** *Mult Scler.* 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14. PMID: 24126064.

Gatopoulou A, Christodoulou DK, Katsanos KH, Bakos D, Mouzas I, Tzouvala M, Theodoropoulou A, Paspatis G, Theocharis G, Thomopoulos K, Giouleme O, Kourikou A, Manolakopoulos S, Zampeli E, Michopoulos S, Karatzas P, Katsaros M, Moschovis D, Orfanoudaki E, Livieratos A, Petrikkou E, Mantzaris GJ. **Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece.** *Eur J Gastroenterol Hepatol.* 2021 Dec 1;33(15 Suppl 1):e615-e624. doi: 10.1097/MEG.0000000000002182. PMID: 34034278.



Vu T, Anthony N, Alsina R, Harvey B, Schleutker A, Farias J, Dang S, Suresh N, Gooch C. **Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.** *Muscle Nerve*. 2021 Sep;64(3):351-357. doi: 10.1002/mus.27345. Epub 2021 Jun 15. PMID: 34076265.

Viel E, Eerdeken M, Kandaswamy P. **Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral Pregabalin.** *Pain Physician*. 2021 Sep;24(6):453-463. PMID: 34554688.

Beecher G, Anderson D, Siddiqi ZA. **Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.** *Neurology*. 2017 Sep 12;89(11):1135-1141. doi: 10.1212/WNL.0000000000004365. Epub 2017 Aug 16. PMID: 28814461.

Tsivgoulis G, Deftereos S, Gobbi C, Gulowsen Celiuș E, Kulakowska A, Maniscalco G, Mendes I, Grigoriadis N. **Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).** *J Cent Nerv Syst Dis*. 2022 Apr 1;14:11795735211069441. doi: 10.1177/11795735211069441. PMID: 35392050; PMCID: PMC8980423.

Zanichelli A, Azin GM, Cristina F, Vacchini R, Caballero T. **Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.** *Orphanet J Rare Dis*. 2018 Apr 10;13(1):51. doi: 10.1186/s13023-018-0797-3. PMID: 29631595; PMCID: PMC5891972.

Warnatz K, Jolles S, Agostini C, Vianello F, Borte M, Bethune C, Grigoriadou S, Richter A, Jain R, Lowe DM, Katelaris C, Milito C, Cook MC. **Subcutaneous Gammanorm® by pump or rapid push infusion: Impact of the device on quality of life in adult patients with primary immunodeficiencies.** *Clin Immunol*. 2022 Mar;236:108938. doi: 10.1016/j.clim.2022.108938. Epub 2022 Feb 1. PMID: 35121105.

- **TSQM as other endpoint:**

Huang WN, Tso TK. **Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.** *Bosn J Basic Med Sci*. 2018 Feb 20;18(1):87-94. doi: 10.17305/bjbm.2017.2214. PMID: 28954205; PMCID: PMC5826680.

Lin HY, Cheng TT, Wang JH, Lee CS, Chen MH, Lei V, Lac C, Gammaitoni AR, Smugar SS, Chen WJ. **Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial.** *Int J Rheum Dis*. 2010 May;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.x. PMID: 20536599.

Bienvenu B, Cozon G, Mataix Y, Lachaud D, Alix A, Hoarau C, Antier D, Hachulla E, Brice S, Viallard JF, Tamisier S, Fauchais AL, Renon-Carron F, Clerson P, Fardini Y, Crave JC, Miossec P. **Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.** *J Clin Immunol*. 2018 May;38(4):503-512. doi: 10.1007/s10875-018-0507-x. Epub 2018 May 31. PMID: 29855752; PMCID: PMC6028863.



Source: PubMed

Search terms: "TSQM" AND "label claim"

Picato

Jubert-Esteve E, Del Pozo-Hernando LJ, Izquierdo-Herce N, Bauzá-Alonso A, Martín-Santiago A, Jones-Caballero M. **Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.** *Actas Dermosifiliogr.* 2015 Oct;106(8):644-50. English, Spanish. doi: 10.1016/j.ad.2015.04.014. Epub 2015 Jun 27. PMID: 26130156.

Tobi Podhaler

Michael W Konstan, Patrick A Flume, Matthias Kappler et al. **Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the eager trial.** *J Cyst Fibros.* 2011 January; 10(1): 54–61. doi:10.1016/j.jcf.2010.10.003

Cuvitru

Suez, D., Stein, M., Gupta, S., Hussain, I., Melamed, I., Paris, K., Darter, A., Bourgeois, C., Fritsch, S., Leibl, H., McCoy, B., Gelmont, D., & Yel, L. (2016). **Efficacy, Safety, and Pharmacokinetics of a Novel Human Immune Globulin Subcutaneous, 20 % in Patients with Primary Immunodeficiency Diseases in North America.** *Journal of clinical immunology*, 36(7), 700–712. <https://doi.org/10.1007/s10875-016-0327-9>

Humira

Kimball AB, Okun MM, Williams DA, Gottlieb AB, Papp KA, Zouboulis CC, Armstrong AW, Kerdel F, Gold MH, Forman SB, Korman NJ, Giamarellos-Bourboulis EJ, Crowley JJ, Lynde C, Reguiat Z, Prens EP, Alwawi E, Mostafa NM, Pinsky B, Sundaram M, Gu Y, Carlson DM, Jemec GB. **Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.** *N Engl J Med.* 2016 Aug 4;375(5):422-34. doi: 10.1056/NEJMoa1504370. PMID: 27518661.

Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Smirnakis K, Xiao S, Kong G, Kuhelj R, Campbell N; NOVA study investigators. **Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial.** *Lancet Neurol.* 2022 Jul;21(7):608-619. doi: 10.1016/S1474-4422(22)00143-0. Epub 2022 Apr 25. PMID: 35483387. Source: PubMed

Tysabri

Ryerson LZ, Foley JF, Defer G, Cohen JA, Arnold DL, Butzkueven H, Cutter G, Giovannoni G, Killestein J, Wiendl H, Sinks S, Kuhelj R, Bodhinathan K, Lasky T. **Exploratory clinical efficacy and patient-reported outcomes from NOVA: A randomized controlled study of intravenous natalizumab 6-week dosing versus continued 4-week dosing for relapsing-remitting multiple sclerosis.** *Mult Scler Relat Disord.* 2023 Apr;72:104561. doi: 10.1016/j.msard.2023.104561. Epub 2023 Feb 11. PMID: 36931078.

Afinitor

Bent Ejlertsen, Guy Jerusalem, Sara Hurvitz, Richard de Boer, Tetiana Taran, Tarek Sahmoud, Howard Burris. **Everolimus Plus Exemestane Versus Everolimus or Capecitabine Monotherapy in Breast Cancer: BOLERO-6.** Presented at St. Gallen International Breast Cancer Conference, March 13–16, 2013, St. Gallen, Switzerland

Source: PubMed
Search term: "tsqm"

Acromegaly

Bernabéu I, Fajardo C, Marazuela M, Cordido F, Venegas EM, de Pablos-Velasco P, Maroto GP, Olvera MP, de Paz IP, Carvalho D, Romero C, De la Cruz G, Escolá CÁ. **Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly.** *Endocrine*. 2020 Jul 28. doi: 10.1007/s12020-020-02424-z. Epub ahead of print. PMID: 32725444.

Kepicoglu H, Hatipoglu E, Bulut I, Darici E, Hizli N, Kadioglu P. **Impact of treatment satisfaction on quality of life of patients with acromegaly.** *Pituitary*. 2014 Dec;17(6):557-63. doi: 10.1007/s11102-013-0544-7. PMID: 24337714.

Actinic Keratosis

Platsidaki E, Kostopoulos N, Panagakis P, Cheliotis G, Antoniou C, Kontochristopoulos G. **The use of ingenol mebutate to treat actinic keratosis in standard clinical practice: a prospective phase IV multicenter observational cohort study.** *Int J Dermatol*. 2020 Jun;59(6):690-697. doi: 10.1111/ijd.14879. Epub 2020 Apr 17. PMID: 32301503.

Jubert-Esteve E, Del Pozo-Hernando LJ, Izquierdo-Herce N, Bauzá-Alonso A, Martín-Santiago A, Jones-Caballero M. **Quality of life and side effects in patients with actinic keratosis treated with ingenol mebutate: a pilot study.** *Actas Dermosifiliogr*. 2015 Oct;106(8):644-50. English, Spanish. doi: 10.1016/j.ad.2015.04.014. Epub 2015 Jun 27. PMID: 26130156.

Stockfleth E, Harwood CA, Serra-Guillén C, Larsson T, Østerdal ML, Skov T. **Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0-015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.** *Br J Dermatol*. 2018 Feb;178(2):433-442. doi: 10.1111/bjd.16048. Epub 2018 Jan 15. PMID: 29030864.

Berman B, Tying S, Nahm WK, Østerdal ML, Petersen AH, Siegel DM. **Three-Day Field Treatment with Ingenol Disoxate (LEO 43204) for Actinic Keratosis: Cosmetic Outcomes and Patient Satisfaction from a Phase II Trial.** *J Clin Aesthet Dermatol*. 2017 Nov;10(11):26-32. Epub 2017 Nov 1. PMID: 29399258; PMCID: PMC5774908.

Actinic Porokeratosis

Lang BM, Peveling-Oberhag A, Zimmer S, Wegner J, Sohn A, Grabbe S, Staubach P. **Effective treatment of disseminated superficial actinic porokeratosis with chemical peels - customary treatment for a rare disease.** *J Dermatolog Treat*. 2020 Nov;31(7):744-748. doi: 10.1080/09546634.2019.1610551. Epub 2019 Aug 12. PMID: 31018713.

Addiction

Pérez de Los Cobos J, Trujols J, Alcaraz S, Siñol N, Lozano Ó, González-Saiz F; Buprenorphine Naloxone Survey Group. **Development and validation of the scale to assess satisfaction with medications for addiction treatment - Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER).** *Int J Drug Policy*. 2018 Aug;58:126-134. doi: 10.1016/j.drugpo.2018.06.007. Epub 2018 Jun 26. PMID: 29957563.

de los Cobos JP, Trujols J, Siñol N, Batlle F. **Development and validation of the scale to assess satisfaction with medications for addiction treatment-methadone for heroin addiction (SASMAT-METHER).** *Drug Alcohol Depend*. 2014 Sep 1;142:79-85. doi: 10.1016/j.drugalcdep.2014.05.024. Epub 2014 Jun 11. PMID: 24975476.

Adult Growth Hormone Deficiency

Johannsson G, Feldt-Rasmussen U, Håkonsson IH, Biering H, Rodien P, Tahara S, Toogood A, Rasmussen MH; **REAL 2 Study Group. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.** Eur J Endocrinol. 2018 May;178(5):491-499. doi: 10.1530/EJE-17-1073. Epub 2018 Mar 2. PMID: 29500310; PMCID: PMC5920019.

Allergic Rhinitis

Crawford B, Stanford RH, Wong AY, Dalal AA, Bayliss MS. **Psychometric validation of the experience with allergic rhinitis nasal spray questionnaire.** Patient Relat Outcome Meas. 2011 Jul;2:127-33. doi: 10.2147/PROM.S19371. Epub 2011 Jun 16. PMID: 22915973; PMCID: PMC3417928.

Canonica GW, Klimek L, Acaster S, Dollner R, Kaulsay R, Lo SH, Price DB, Scadding GK, Valovirta E, Ziegelmayer P. **Burden of allergic rhinitis and impact of MP-AzeFlu from the patient perspective: pan European patient survey.** Curr Med Res Opin. 2021 Jul;37(7):1259-1272. doi: 10.1080/03007995.2021.1911973. Epub 2021 Apr 20. PMID: 33840316.

Aguilar D, Arias A, Báez C, González S, Hernández D, Linares FJ, López A, Macías A, Martínez A, Martínez HM, Martínez N, Mogica MD, Paz D, Rojo I, Sánchez A. **Estudio multicéntrico de satisfacción con ebastina de disolución rápida 20 mg/día en pacientes mexicanos con rinitis alérgica [Multicenter study of satisfaction with fast-dissolving ebastine, 20 mg/ day, in Mexican patients with allergic rhinitis].** Rev Alerg Mex. 2009 Mar-Apr;56(2):36-40. Spanish. PMID: 19526952.

Amyotrophic Lateral Sclerosis

Meyer T, Funke A, Münch C, Kettemann D, Maier A, Walter B, Thomas A, Spittel S. **Real world experience of patients with amyotrophic lateral sclerosis (ALS) in the treatment of spasticity using tetrahydrocannabinol:cannabidiol (THC:CBD).** BMC Neurol. 2019 Sep 7;19(1):222. doi: 10.1186/s12883-019-1443-y. PMID: 31493784; PMCID: PMC6732193.

Antihypertension medication

Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. **Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications.** Health Qual Life Outcomes. 2009 Apr 27;7:36. doi: 10.1186/1477-7525-7-36. PMID: 19397800; PMCID: PMC2678998.

Asthma

Albert Roger, Nathalie Depreux, Yani Jurgens, Matthew D. Heath, Gloria Garcia, & Murray A. Skinner. **A novel and well tolerated mite allergoid subcutaneous immunotherapy: evidence of clinical and immunologic efficacy.** *Immunity, Inflammation and Disease* 2014; 2(2): 92–98.

George M, Balantac Z, Gillette C, Farooqui N, Tervonen T, Thomas C, Gilbert I, Gandhi H, Israel E. **Suboptimal Control of Asthma Among Diverse Patients: A US Mixed Methods Focus Group Study.** J Asthma Allergy. 2022 Oct 22;15:1511-1526. doi: 10.2147/JAA.S377760. PMID: 36313858; PMCID: PMC9601558.

Diane Whalley, Tanaz Petigara, Lawrence Rasouliyan, Keisuke Tobe & Kaan Tunceli (2017). **Early patient experiences with montelukast orally disintegrating tablets in Japan: a cross-sectional survey of treatment satisfaction in patients with asthma and/or allergic rhinitis.** *Current Medical Research and Opinion.* 33:2, 215-223.

Gouder C, Gouder S, Montefort S. **Self-reported satisfaction of patients receiving omalizumab for severe allergic asthma in Malta.** Biologicals. 2019 Jul;60:24-27. doi: 10.1016/j.biologicals.2019.06.004. Epub 2019 Jun 18. PMID: 31227304.

Aggarwal AN, Kumari R, Grover S. **Patient Satisfaction With Inhaled Medication for Asthma.** Respir Care. 2018 Jul;63(7):859-864. doi: 10.4187/respcare.05544. Epub 2018 Mar 20. PMID: 29559538.

Padró C, Gutiérrez D, Moreno F, Parra A, Rial MJ, Lleonart R, Torán-Barona C, Justicia JL, Roger A. **Effectiveness and safety of a microcrystalline tyrosine-adjuvanted Dermatophagoides pteronyssinus allergoid immunotherapy in adult patients with allergic asthma and rhinitis: A real-life prospective observational study.** *Immun Inflamm Dis.* 2022 May;10(5):e585. doi: 10.1002/iid3.585. PMID: 35478444; PMCID: PMC9017636.

Antidepressant/antipsychotics treatment

Aljumah K, Ahmad Hassali A, AlQhatani S. **Examining the relationship between adherence and satisfaction with antidepressant treatment.** *Neuropsychiatr Dis Treat.* 2014 Aug 4;10:1433-8. doi: 10.2147/NDT.S67008. PMID: 25120364; PMCID: PMC4128845.

Kwon JS, Kim SN, Han J, Lee SI, Chang JS, Choi JS, Lee HJ, Cho SJ, Jun TY, Lee SH, Han C, Lee KU, Lee KK, Lee E. **Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics.** *Int Clin Psychopharmacol.* 2015 Nov;30(6):320-8. doi: 10.1097/YIC.000000000000093. PMID: 26196188; PMCID: PMC4593469.

Atrial Fibrillation

Ungar L, Rodriguez F, Hellkamp AS, Becker RC, Berkowitz SD, Breithardt G, Fox KAA, Hacke W, Halperin JL, Hankey GJ, Nessel CC, Singer DE, Patel MR, Piccini JP, Mahaffey KW. **Patient-Reported Satisfaction and Study Drug Discontinuation: Post-Hoc Analysis of Findings from ROCKET AF.** *Cardiol Ther.* 2019 Dec;8(2):283-295. doi: 10.1007/s40119-019-00146-6. Epub 2019 Aug 2. PMID: 31376090; PMCID: PMC6828909.

Salmasi S, Adelakun A, Safari A, Kwan L, MacGillivray J, Andrade JG, Deyell MW, Kapanen A, Loewen P. **Satisfaction With Oral Anticoagulants Among Patients With Atrial Fibrillation: A Prospective Observational Study.** *CJC Open.* 2021 Jun 29;3(11):1347-1356. doi: 10.1016/j.cjco.2021.06.015. PMID: 34901803; PMCID: PMC8640622.

Watanabe-Fujinuma E, Banderas BF, Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Akiyama S, Briere JB, Dickie G, Cano SJ. **Psychometric validation of anti-clot treatment scale and treatment satisfaction questionnaire for medication version II in Japanese patients with atrial fibrillation.** *J Med Econ.* 2019 Aug;22(8):798-805. doi: 10.1080/13696998.2019.1609003. Epub 2019 May 13. PMID: 30995146.

Oh S, Kim JS, Oh YS, Shin DG, Pak HN, Hwang GS, Choi KJ, Kim JB, Lee MY, Park HW, Kim DK, Jin ES, Park J, Oh IY, Shin DH, Park HS, Kim JH, Kim NH, Ahn MS, Seo BJ, Kim YJ, Kang S, Lee J, Kim YH. **Quality of Anticoagulation and Treatment Satisfaction in Patients with Non-Valvular Atrial Fibrillation Treated with Vitamin K Antagonist: Result from the KOREAN Atrial Fibrillation Investigation II.** *J Korean Med Sci.* 2018 Nov 21;33(49):e323. doi: 10.3346/jkms.2018.33.e323. PMID: 30505257; PMCID: PMC6262187.

Okumura Y, Yokoyama K, Matsumoto N, Tachibana E, Kuronuma K, Oiwa K, Matsumoto M, Kojima T, Arima K, Kotani T, Nomoto K, Ikeya Y, Fukushima S, Onikura M, Suzuki Y, Fujita M, Ando H, Ishikawa N, Hirayama A; SAKURA AF Registry Investigators. **Patient Satisfaction with Direct Oral Anticoagulants and Warfarin.** *Int Heart J.* 2018 Nov 28;59(6):1266-1274. doi: 10.1536/ihj.17-649. Epub 2018 Oct 25. PMID: 30369576.

Koretsune Y, Kumagai K, Uchiyama S, Yamashita T, Yasaka M, Watanabe-Fujinuma E, Banderas BF, Akiyama S, Okayama Y, Briere JB, Dickie G, Cano SJ. **Patient-reported treatment satisfaction with rivaroxaban in Japanese non-valvular atrial fibrillation patients: an observational study.** *Curr Med Res Opin.* 2018 Dec;34(12):2157-2164. doi: 10.1080/03007995.2018.1507315. Epub 2018 Aug 14. PMID: 30067119.

Katerenchuk V, Duarte GS, Martins E Pereira G, Fernandes RM, Ferreira JJ, Pinto FJ, Costa J, Caldeira D. **Satisfaction of Patients with Nonvitamin K Anticoagulants Compared to Vitamin K Antagonists: a Systematic Review and Meta-analysis.** *Thromb Haemost.* 2021 Mar;121(3):366-382. doi: 10.1055/s-0040-1716752. Epub 2020 Nov 7. PMID: 33160289.

Breast Cancer

Dawn L. Hershman, Lawrence H. Kushi, Grace Clarke Hillyer, Ellie Coromilas, Donna Buono, Lois Lamerato, Dana H. Bovbjerg, Jeanne S. Mandelblatt, Wei-Yann Tsai, Xiaobo Zhong, Judith S. Jacobson, Jason D. Wright, and Alfred I. Neugut. **Psychosocial Factors Related to Non-persistence with Adjuvant Endocrine Therapy among Women with Breast Cancer: The Breast Cancer Quality of Care Study (BQUAL).** *Breast Cancer Res Treat.* 2016 May; 157(1): 133–143.

Cancer

Rauck R, Parikh N, Dillaha L, Barker J, Stearns L. **Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain.** *Pain Pract.* 2015 Jul;15(6):554-63. doi: 10.1111/papr.12225. Epub 2014 Jul 25. PMID: 25060406.

Peppelman M, Nguyen KP, Alkemade HA, Maessen-Visch B, Hendriks JC, van Erp PE, Adang EM, Gerritsen MJ. **Diagnosis of Basal Cell Carcinoma by Reflectance Confocal Microscopy: Study Design and Protocol of a Randomized Controlled Multicenter Trial.** *JMIR Res Protoc.* 2016 Jun 30;5(2):e114. doi: 10.2196/resprot.5757. PMID: 27363577; PMCID: PMC4945846.

Chronic Inflammatory Demyelinating Polyneuropathy

Hartung HP, Mallick R, Brill V, Lewis RA, Sobue G, Lawo JP, Mielke O, Durn BL, Cornblath DR, Merkies ISJ, van Schaik IN; PATH study group. **Patient-reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study.** *Eur J Neurol.* 2020 Jan;27(1):196-203. doi: 10.1111/ene.14056. Epub 2019 Sep 23. PMID: 31400231.

Vu T, Anthony N, Alsina R, Harvey B, Schleutker A, Farias J, Dang S, Suresh N, Gooch C. **Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.** *Muscle Nerve.* 2021 Sep;64(3):351-357. doi: 10.1002/mus.27345. Epub 2021 Jun 15. PMID: 34076265.

Chronic Obstructive Pulmonary Disease

Contoli M, Rogliani P, Di Marco F, Braido F, Corsico AG, Amici CA, Piro R, Sarzani R, Lessi P, Scognamillo C, Scichilone N, Santus P; SAT Study Group. **Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study.** *Ther Adv Respir Dis.* 2019 Jan-Dec;13:1753466619888128. doi: 10.1177/1753466619888128. PMID: 31760881; PMCID: PMC6878607.

Baiardini I, Contoli M, Corsico AG, Scognamillo C, Ferri F, Scichilone N, Rogliani P, Di Marco F, Santus P, Braido F. **Exploring the Relationship between Disease Awareness and Outcomes in Patients with Chronic Obstructive Pulmonary Disease.** *Respiration.* 2021;100(4):291-297. doi: 10.1159/000513953. Epub 2021 Mar 11. PMID: 33706318; PMCID: PMC8220921.

Chronic diseases

Delestras S, Roustit M, Bedouch P, Minoves M, Dobremez V, Mazet R, Lehmann A, Baudrant M, Allenet B. **Comparison between two generic questionnaires to assess satisfaction with medication in chronic diseases.** *PLoS One.* 2013;8(2):e56247. doi: 10.1371/journal.pone.0056247. Epub 2013 Feb 20. PMID: 23437104; PMCID: PMC3577836.

Bhalerao MS, Bolshete PM, Swar BD, Bangera TA, Kolhe VR, Tambe MJ, Wade MP, Bhowate SD, Sonje UB, Gogtay NJ, Thatte UM. **Use of and satisfaction with complementary and alternative medicine in four chronic diseases: a cross-sectional study from India.** *Natl Med J India.* 2013 Mar-Apr;26(2):75-8. PMID: 24093979.

Atkinson MJ, Sinha A, Hass SL, Colman SS, Kumar RN, Brod M, Rowland CR. **Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease.** *Health Qual Life Outcomes.* 2004 Feb 26;2:12. doi: 10.1186/1477-7525-2-12. PMID: 14987333; PMCID: PMC398419.

Constipation

Koppen IJN, van Wassenauer EA, Barendsen RW, Brand PL, Benninga MA. **Adherence to Polyethylene Glycol Treatment in Children with Functional Constipation Is Associated with Parental Illness Perceptions, Satisfaction with Treatment, and Perceived Treatment Convenience.** J Pediatr. 2018 Aug;199:132-139.e1. doi: 10.1016/j.jpeds.2018.03.066. Epub 2018 May 10. PMID: 29754864.

Baaleman DF, Wegh CAM, Hoogveld MTA, Benninga MA, Koppen IJN. **Transanal Irrigation in Children: Treatment Success, Quality of Life, Adherence, Patient Experience and Independence.** J Pediatr Gastroenterol Nutr. 2022 Jun 7. doi: 10.1097/MPG.0000000000003515. Epub ahead of print. PMID: 35675698.

Convergent Validation

Pérez de Los Cobos J, Trujols J, Alcaraz S, Siñol N, Lozano Ó, González-Saiz F; Buprenorphine Naloxone Survey Group. **Development and validation of the scale to assess satisfaction with medications for addiction treatment - Buprenorphine-naloxone for heroin addiction (SASMAT-BUNHER).** Int J Drug Policy. 2018 Aug;58:126-134. doi: 10.1016/j.drugpo.2018.06.007. Epub 2018 Jun 26. PMID: 29957563.

Coronary Disease

Mulchandani R, Lyngdoh T, Chakraborty P, Kakkar AK. **Satisfaction With Statin Treatment Among Adult Coronary Artery Disease Patients: An Experience From a Resource-Constrained Setting.** Heart Lung Circ. 2019 Dec;28(12):1788-1794. doi: 10.1016/j.hlc.2018.10.024. Epub 2018 Dec 10. PMID: 30704841.

Liberato AC, Rodrigues RC, São-João TM, Alexandre NM, Gallani MC. **Satisfaction with medication in coronary disease treatment: psychometrics of the Treatment Satisfaction Questionnaire for Medication.** Rev Lat Am Enfermagem. 2016 Jun 7;24:e2705. doi: 10.1590/1518-8345.0745.2705. PMID: 27276018; PMCID: PMC4915802.

COVID-19

Balkrishna A, Raj P, Singh P, Varshney A. **Influence of Patient-Reported Treatment Satisfaction on Psychological Health and Quality of Life Among Patients Receiving Divya-Swasari-Coronil-Kit Against COVID-19: Findings from a Cross-Sectional "SATISFACTION COVID" Survey.** Patient Prefer Adherence. 2021 Apr 29;15:899-909. doi: 10.2147/PPA.S302957. PMID: 33958858; PMCID: PMC8096451.

Criterion-related validity

Katusiime B, Corlett SA, Krska J. **Development and validation of a revised instrument to measure burden of long-term medicines use: the Living with Medicines Questionnaire version 3.** Patient Relat Outcome Meas. 2018 May 28;9:155-168. doi: 10.2147/PROM.S151143. PMID: 29881317; PMCID: PMC5978458.

Crohn's disease

Gilet H, Arnould B, Fofana F, Clerson P, Colombel JF, D'Hondt O, Faure P, Hagège H, Nachury M, Nahon S, Tucac G, Vandromme L, Cazala-Tellinge I, Thibout E. **Measuring patients' satisfaction with their anti-TNF treatment in severe Crohn's disease: scoring and psychometric validation of the Satisfaction for Patients in Crohn's disease Questionnaire (SPACE-Q(©)).** Patient Prefer Adherence. 2014 Dec 4;8:1671-81. doi: 10.2147/PPA.S72004. PMID: 25525343; PMCID: PMC4262217.



Cystic Fibrosis

Regnault A, et al, **Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis**, *J Cyst Fibros* (2012).

Greenberg J, Palmer JB, Chan WW, Correia CE, Whalley D, Shannon P, Sawicki GS. **Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder**. *Patient Prefer Adherence*. 2016 Oct 26;10:2163-2169. doi: 10.2147/PPA.S102234. PMID: 27822017; PMCID: PMC5087789.

Blasi F, Carnovale V, Cimino G, Lucidi V, Salvatore D, Messore B, Bartezaghi M, Muscianisi E, Porpiglia PA; FREE study group. **Treatment compliance in cystic fibrosis patients with chronic Pseudomonas aeruginosa infection treated with tobramycin inhalation powder: The FREE study**. *Respir Med*. 2018 May;138:88-94. doi: 10.1016/j.rmed.2018.03.034. Epub 2018 Mar 31. PMID: 29724399.

Dermatitits

Oosterhaven JAF, Spekhorst LS, Zhang J, Voorberg AN, Romeijn GLE, Boesjes CM, de Graaf M, de Bruin-Weller MS, Schuttelaar MLA. **Eczema control and treatment satisfaction in atopic dermatitis patients treated with dupilumab - a cross-sectional study from the BioDay registry**. *J Dermatolog Treat*. 2021 Jun 21:1-4. doi: 10.1080/09546634.2021.1937485. Epub ahead of print. PMID: 34151695.

Diabetes

Khdour MR, Awadallah HB, Al-Hamed DH. **Treatment Satisfaction and Quality of Life among Type 2 Diabetes Patients: A Cross-Sectional Study in West Bank, Palestine**. *J Diabetes Res*. 2020 Aug 25; 2020: Article ID 1834534.

Donatti C, Wild D, Horblyuk R, Beusterien KM, Anderson RT, Arondekar B, Dibenedetti DB. **Psychometric evaluation of the Satisfaction with Oral Anti-Diabetic Agent Scale (SOADAS)**. *Diabetes Res Clin Pract*. 2008 Apr;80(1):108-13. doi: 10.1016/j.diabres.2007.11.005. Epub 2008 Jan 18. PMID: 18207601.

Forst T, Koch C, Dworak M. **Vildagliptin versus insulin in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea: results from a randomized, 24 week study**. *Curr Med Res Opin*. 2015 Jun;31(6):1079-84. doi: 10.1185/03007995.2015.1039936. Epub 2015 May 20. PMID: 25867771.

Pagkalos E, Thanopoulou A, Sampanis C, Bousboulas S, Melidonis A, Tentolouris N, Alexandrides T, Migdalis I, Karamousouli E, Papanas N. **The Real-Life Effectiveness and Care Patterns of Type 2 Diabetes Management in Greece**. *Exp Clin Endocrinol Diabetes*. 2018 Jan;126(1):53-60. doi: 10.1055/s-0043-109242. Epub 2017 Jul 13. PMID: 28704857.

Zameer R, Kamin M, Raja U, Wahab MU, Ishtiaq O, Raashid K, Ahmed N, Rehman AU. **Effectiveness, Safety, and Patient Satisfaction of Liraglutide in Type 2 Diabetic Patients**. *Cureus*. 2020 Aug 22;12(8):e9937. doi: 10.7759/cureus.9937. PMID: 32864274; PMCID: PMC7449611.

Stargardt T, Gonder-Frederick L, Krobot KJ, Alexander CM. **Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes**. *Health Qual Life Outcomes*. 2009 Oct 22;7:91. doi: 10.1186/1477-7525-7-91. PMID: 19849828; PMCID: PMC2770562.

Zyoud SH, Al-Jabi SW, Sweileh WM, Arandi DA, Dabeek SA, Esawi HH, Atyeh RH, Abu-Ali HA, Sleet YI, Abd-Alfatah BM, Awang R. **Relationship of treatment satisfaction to health-related quality of life among Palestinian patients with type 2 diabetes mellitus: Findings from a cross-sectional study**. *J Clin Transl Endocrinol*. 2015 Mar 31;2(2):66-71. doi: 10.1016/j.jcte.2015.03.002. PMID: 29159112; PMCID: PMC5685049.

Dry Eye Disease

Kreimeier M, Sorkin N, Boutin T, Slomovic AR, Rootman DS, Chan CC. **Patient-reported outcomes of autologous serum tears for the treatment of dry eye disease in a large cohort.** *Ocul Surf.* 2019 Oct;17(4):743-746. doi: 10.1016/j.jtos.2019.07.003. Epub 2019 Jul 2. PMID: 31276828.

Duchenne Muscular Dystrophy (DMD)

Wood CL, Hollingsworth KG, Hughes E, Punniyakodi S, Muni-Lofra R, Mayhew A, Mitchell RT, Guglieri M, Cheetham TD, Straub V. **Pubertal induction in adolescents with DMD is associated with high satisfaction, gonadotropin release and increased muscle contractile surface area.** *Eur J Endocrinol.* 2021 Jan;184(1):67-79. doi: 10.1530/EJE-20-0709. PMID: 33112266.

Guglieri M, Bushby K, McDermott MP, Hart KA, Tawil R, Martens WB, Herr BE, McColl E, Speed C, Wilkinson J, Kirschner J, King WM, Eagle M, Brown MW, Willis T, Griggs RC; FOR-DMD Investigators of the Muscle Study Group, Straub V, van Ruiten H, Childs AM, Ciafaloni E, Shieh PB, Spinty S, Maggi L, Baranello G, Butterfield RJ, Horrocks IA, Roper H, Alhaswani Z, Flanigan KM, Kuntz NL, Manzur A, Darras BT, Kang PB, Morrison L, Krzesniak-Swinarska M, Mah JK, Mongini TE, Ricci F, von der Hagen M, Finkel RS, O'Reardon K, Wicklund M, Kumar A, McDonald CM, Han JJ, Joyce N, Henricson EK, Schara-Schmidt U, Gangfuss A, Wilichowski E, Barohn RJ, Statland JM, Campbell C, Vita G, Vita GL, Howard JF Jr, Hughes I, McMillan HJ, Pegoraro E, Bello L, Burnette WB, Thangarajah M, Chang T. **Effect of Different Corticosteroid Dosing Regimens on Clinical Outcomes in Boys With Duchenne Muscular Dystrophy: A Randomized Clinical Trial.** *JAMA.* 2022 Apr 19;327(15):1456-1468. doi: 10.1001/jama.2022.4315. PMID: 35381069; PMCID: PMC8984930.

Dyslipidemia

Rodríguez Arroyo LA, Díaz Rodríguez A, Pintó Sala X, Coca Payeras A, Rius Tarruella J. **Efectividad y satisfacción del tratamiento de la dislipidemia con pitavastatin estudio observacional, postautorización, descriptivo y multicéntrico (estudio REINA) [Effectivity and satisfaction with the treatment for dyslipidemia with pitavastatin. Multicentric, descriptive, post authorised and observational study (REINA study)].** *Clin Investig Arterioscler.* 2014 Sep-Oct;26(5):205-17. Spanish. doi: 10.1016/j.arteri.2014.01.005. Epub 2014 Mar 20. PMID: 24656917.

Epilepsy

Sweileh WM, Ihabesheh MS, Jarar IS, Taha AS, Sawalha AF, Zyoud SH, Jamous RM, Morisky DE. **Self-reported medication adherence and treatment satisfaction in patients with epilepsy.** *Epilepsy Behav.* 2011 Jul;21(3):301-5. doi: 10.1016/j.yebeh.2011.04.011. Epub 2011 May 14. PMID: 21576040.

Erythematous-squamous disorders

Navarro-Triviño FJ, Ruiz-Villaverde R. **Successful treatment of erythematous-squamous disorders of the external auditory canal with tacrolimus and clotrimazole in otic oil: Our experience in 25 patients.** *Dermatol Ther.* 2020 Nov;33(6):e14471. doi: 10.1111/dth.14471. Epub 2020 Nov 4. PMID: 33112026.

Flushing bother

Rhodes T, Norquist JM, Sisk CM, McQuarrie K, Trovato A, Liao J, Miller T, Maccubbin D, Watson DJ. **The association of flushing bother, impact, treatment satisfaction and discontinuation of niacin therapy.** *Int J Clin Pract.* 2013 Dec;67(12):1238-46. doi: 10.1111/ijcp.12213. Epub 2013 Sep 15. PMID: 24102896.

Gastrointestinal

Häcker F, Morck H. **Self-medication of upper gastrointestinal symptoms with hydrotalcite: a noninterventional community pharmacy study on drug usage and patient satisfaction.** *Int J Clin Pharmacol Ther.* 2012 Feb;50(2):87-99. doi: 10.5414/cp201576. PMID: 22257575.

Geriatrics

Sakr S, Hallit S, Haddad M, Khabbaz LR. **Assessment of potentially inappropriate medications in elderly according to Beers 2015 and STOPP criteria and their association with treatment satisfaction.** Arch Gerontol Geriatr. 2018 Sep-Oct;78:132-138. doi: 10.1016/j.archger.2018.06.009. Epub 2018 Jun 22. PMID: 29958151.

Gout

Wei Zhou, Jinjin Zhu, Jiabin Guo, Huamao Chen, Xiaomei Zhang, Zhifeng Gu, Fengyan Zhou & Chen Dong (2020) **Health-related quality of life assessed by gout impact scale (GIS) in Chinese patients with gout, Current Medical Research and Opinion**, DOI: [10.1080/03007995.2020.1840341](https://doi.org/10.1080/03007995.2020.1840341)

Khanna PP, Shiozawa A, Walker V, Bancroft T, Esoi B, Akhras KS, Khanna D. **Health-related quality of life and treatment satisfaction in patients with gout: results from a cross-sectional study in a managed care setting. Patient Prefer Adherence.** 2015 Jul 9;9:971-81. doi: 10.2147/PPA.S83700. PMID: 26185426; PMCID: PMC4501348.

Hemophilia A

Di Minno G, Santagostino E, Morfini M, Ettorre C, Cultrera D, Baldacci E, Russo E, Gallucci C. **Patient satisfaction and acceptability of an on-demand and on-prophylaxis device for factor VIII delivery in patients with hemophilia A.** Patient Prefer Adherence. 2019 Jan 31;13:233-240. doi: 10.2147/PPA.S175254. PMID: 30774319; PMCID: PMC6362933.

Park YS, Hwang TJ, Cho GJ, Kim SK, Park SK, Kim JY, Baek HJ, Kim YJ, Lee HJ, Shin JS, Nam CM, Sun J, Yoo KY. **Patients' and parents' satisfaction with, and preference for, haemophilia A treatments: a cross-sectional, multicentre, observational study.** Haemophilia. 2021 Jul;27(4):563-573. doi: 10.1111/hae.14304. Epub 2021 Jun 15. PMID: 34128300; PMCID: PMC8362144.

Hematologic Disorders

Sweiss K, Anderson J, Wirth S, Oh A, Quigley JG, Khan I, Saraf S, Mactal-Haaf C, Rondelli D, Patel P. **A prospective study of intravenous pentamidine for PJP prophylaxis in adult patients undergoing intensive chemotherapy or hematopoietic stem cell transplant.** Bone Marrow Transplant. 2018 Mar;53(3):300-306. doi: 10.1038/s41409-017-0024-1. Epub 2017 Dec 21. PMID: 29269796.

Hereditary Angioedema

Zanichelli A, Azin GM, Cristina F, Vacchini R, Caballero T. **Safety, effectiveness, and impact on quality of life of self-administration with plasma-derived nanofiltered C1 inhibitor (Berinert®) in patients with hereditary angioedema: the SABHA study.** Orphanet J Rare Dis. 2018 Apr 10;13(1):51. doi: 10.1186/s13023-018-0797-3. PMID: 29631595; PMCID: PMC5891972.

Lumry WR, Craig T, Zuraw B, Longhurst H, Baker J, Li HH, Bernstein JA, Anderson J, Riedl MA, Manning ME, Keith PK, Levy DS, Caballero T, Banerji A, Gower RG, Farkas H, Lawo JP, Pragst I, Machnig T, Watson DJ. **Health-Related Quality of Life with Subcutaneous C1-Inhibitor for Prevention of Attacks of Hereditary Angioedema.** J Allergy Clin Immunol Pract. 2018 Sep-Oct;6(5):1733-1741.e3. doi: 10.1016/j.jaip.2017.12.039. Epub 2018 Jan 31. PMID: 29391286.

Hidradenitis suppurativa

Docampo-Simón A, Beltrá-Picó I, Sánchez-Pujol MJ, Fuster-Ruiz-de-Apodaca R, Selva-Otaolaurruchi J, Betlloch I, Pascual JC. **Topical 15% Resorcinol Is Associated with High Treatment Satisfaction in Patients with Mild to Moderate Hidradenitis Suppurativa.** Dermatology. 2021 Apr 22:1-4. doi: 10.1159/000515450. Epub ahead of print. PMID: 33887735.

Hypertension

Derbew Fikadu Berhe, Katja Taxis, Flora M. Haaijer-Ruskamp, Afework Mulugeta, Yewondwossen Tadesse Mengistu, Johannes G. M. Burgerhof and Peter G. M. Mol1. **Impact of adverse drug events and treatment satisfaction on patient adherence with antihypertensive medication – a study in ambulatory patients.** Br J Clin Pharmacol (2017); 83: 2107–2117.

Al-Jabi SW, Zyoud SH, Sweileh WM, Wildali AH, Saleem HM, Aysa HA, Badwan MA, Awang R. **Relationship of treatment satisfaction to health-related quality of life: findings from a cross-sectional survey among hypertensive patients in Palestine.** Health Expect. 2015 Dec;18(6):3336-48. doi: 10.1111/hex.12324. Epub 2014 Dec 7. PMID: 25484002; PMCID: PMC5810714.

Ajayi DT, Adedokun BO, Owoeye DO, Akpa OM. **Treatment Satisfaction and Medication Adherence Among Hypertensive Patients Seeking Care in Selected Hospitals in Ibadan, Nigeria.** Arch Basic Appl Med. 2018 Feb;6(1):67-72. PMID: 29930986; PMCID: PMC6007840.

Saarti S, Hajj A, Karam L, Jabbour H, Sarkis A, El Osta N, Rabbaa Khabbaz L. **Association between adherence, treatment satisfaction and illness perception in hypertensive patients.** J Hum Hypertens. 2016 May;30(5):341-5. doi: 10.1038/jhh.2015.86. Epub 2015 Aug 27. PMID: 26310182.

Jneid S, Jabbour H, Hajj A, Sarkis A, Licha H, Hallit S, Khabbaz LR. **Quality of Life and Its Association With Treatment Satisfaction, Adherence to Medication, and Trust in Physician Among Patients With Hypertension: A Cross-Sectional Designed Study.** J Cardiovasc Pharmacol Ther. 2018 Nov;23(6):532-542. doi: 10.1177/1074248418784292. Epub 2018 Jun 19. PMID: 29916266.

Zyoud SH, Al-Jabi SW, Sweileh WM, Morisky DE. **Relationship of treatment satisfaction to medication adherence: findings from a cross-sectional survey among hypertensive patients in Palestine.** Health Qual Life Outcomes. 2013 Nov 6;11:191. doi: 10.1186/1477-7525-11-191. PMID: 24195638; PMCID: PMC4228307.

Liberato ACS, São João TM, Jannuzzi FF, Landaas EJ, Wongchareon K, Rodrigues RCM. **Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4): Ceiling and Floor Effects, Reliability, and Known-Group Validity in Brazilian Outpatients With Hypertension.** Value Health Reg Issues. 2020 Dec;23:150-156. doi: 10.1016/j.vhri.2020.07.578. Epub 2020 Nov 4. PMID: 33158803.

Hypoglycaemia

Marrett E, Stargardt T, Mavros P, Alexander CM. **Patient-reported outcomes in a survey of patients treated with oral antihyperglycaemic medications: associations with hypoglycaemia and weight gain.** Diabetes Obes Metab. 2009 Dec;11(12):1138-44. doi: 10.1111/j.1463-1326.2009.01123.x. Epub 2009 Sep 16. PMID: 19758360

Hypogonadism

Lee J, Brock G, Barkin J, Bryson N, Gronski MA, Ormsby R. **The My-T study: Patient satisfaction and preference comparing topical and nasal testosterone therapies.** Can Urol Assoc J. 2019 Feb 26;13(12):384-389. doi: 10.5489/cuaj.5680. Epub ahead of print. PMID: 30817284; PMCID: PMC6892698.

Intraocular Pressure (IOP)/Glaucoma

Onoe H, Hirooka K, Nagayama M, Mochizuki H, Hirota A, Suzuki K, Sagara T, Kiuchi Y. **The Efficacy, Safety, and Satisfaction Associated with Switching from Brinzolamide or Brimonidine to Brinzolamide/Brimonidine in Open-Angle Glaucoma Patients.** J Pers Med. 2022 Dec 13;12(12):2057. doi: 10.3390/jpm12122057. PMID: 36556275; PMCID: PMC9782658.

Onoe H, Hirooka K, Nagayama M, Hirota A, Mochizuki H, Sagara T, Suzuki K, Okumichi H, Kiuchi Y. **The Efficacy, Safety and Satisfaction Associated with Switching from Brinzolamide 1% and Brimonidine 0.1% to a Fixed Combination of Brinzolamide 1% and Brimonidine 0.1% in Glaucoma Patients.** J Clin Med. 2021 Nov 10;10(22):5228. doi: 10.3390/jcm10225228. PMID: 34830510; PMCID: PMC8622027.

Atkinson MJ, Stewart WC, Fain JM, Stewart JA, Dhawan R, Mozaffari E, Lohs J. **A new measure of patient satisfaction with ocular hypotensive medications: the Treatment Satisfaction Survey for Intraocular Pressure (TSS-IOP).** Health Qual Life Outcomes. 2003 Nov 15;1:67. doi: 10.1186/1477-7525-1-67. PMID: 14617372; PMCID: PMC280705.

Irritable bowel syndrome

Neri L, Iovino P; Laxative Inadequate Relief Survey (LIRS) Group. **Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipation-predominant irritable bowel syndrome and functional constipation.** *Neurogastroenterol Motil.* 2016 Apr;28(4):581-91. doi: 10.1111/nmo.12758. Epub 2016 Feb 12. PMID: 26867677.

Taxonera C, Martínez-Montiel MP, Barreiro-de-Acosta M, Vera I, Lorente R, Vega P, Diz-Lois MT, Fuentes Coronel AM, Pérez Calle JL, Casis B, Ferreiro-Iglesias R, Calvo M, Olivares D, Alba C. **Preferences and satisfaction of IBD patients after switching from adalimumab 40 mg weekly to 80 mg every other week given as a single injection: the ADASCAL study.** *Therap Adv Gastroenterol.* 2021 Nov 24;14:17562848211056157. doi: 10.1177/17562848211056157. PMID: 35116079; PMCID: PMC8804976.

Primary Immunodeficiency

Mallick R, Henderson T, Lahue BJ, Kafal A, Bassett P, Scalchunes C. **Subcutaneous immunoglobulin in primary immunodeficiency - impact of training and infusion characteristics on patient-reported outcomes.** *BMC Immunol.* 2020 Aug 10;21(1):47. doi: 10.1186/s12865-020-00371-y. PMID: 32778048; PMCID: PMC7418302.

Meckley LM, Wu Y, Ito D, Berner T, McCoy B, Yel L. **Patient experience with subcutaneous immunoglobulin 20%, Ig20Gly, for primary immunodeficiency diseases: a prespecified post hoc analysis of combined data from 2 pivotal trials.** *BMC Immunol.* 2020 May 4;21(1):24. doi: 10.1186/s12865-020-00346-z. PMID: 32366233; PMCID: PMC7197164.

Bienvenu B, Cozon G, Mataix Y, Lachaud D, Alix A, Hoarau C, Antier D, Hachulla E, Brice S, Viallard JF, Tamisier S, Fauchais AL, Renon-Carron F, Clerson P, Fardini Y, Crave JC, Miossec P. **Rapid Push vs Pump-Infused Subcutaneous Immunoglobulin Treatment: a Randomized Crossover Study of Quality of Life in Primary Immunodeficiency Patients.** *J Clin Immunol.* 2018 May;38(4):503-512. doi: 10.1007/s10875-018-0507-x. Epub 2018 May 31. PMID: 29855752; PMCID: PMC6028863.

Clementina Canessa,¹ Jessica Iacopelli,¹ Antonio Pecoraro, Giuseppe Spadaro, Andrea Matucci, Cinzia Milito, Alessandra Vultaggio, Carlo Agostini, Francesco Cinetto, Maria Giovanna Danieli, Simona Gambini, Carolina Marasco, Antonino Trizzino, Angelo Vacca, Domenico De Mattia, Baldassarre Martire, Alessandro Plebani, Mario Di Gioacchino, Alessia Gatta, Andrea Finocchi, Francesco Licciardi, Silvana Martino, Marco De Carli, Viviana Moschese and Chiara Azzari. **Shift from intravenous or 16% subcutaneous replacement therapy to 20% subcutaneous immunoglobulin in patients with primary antibody deficiencies.** *International Journal of Immunopathology and Pharmacology* 2017, Vol. 30(1): 73–82.

Juvenile Idiopathic Arthritis

Tollisen A, Flatø B, Selvaag AM, Aasland A, Ingebrigtsen T, Sagen J, Lerdal A. **Treatment Satisfaction with and Adherence to Disease-Modifying Antirheumatic Drugs in Adult Patients with Juvenile Idiopathic Arthritis.** *Arthritis Care Res (Hoboken).* 2019 Nov 23. doi: 10.1002/acr.24113. Epub ahead of print. PMID: 31758669.

Lipodystrophic Syndromes

Vatier C, Kalbasi D, Vantghem MC, Lascols O, Jéru I, Dagueneil A, Gautier JF, Buyse M, Vigouroux C. **Adherence with metreleptin therapy and health self-perception in patients with lipodystrophic syndromes.** *Orphanet J Rare Dis.* 2019 Jul 12;14(1):177. doi: 10.1186/s13023-019-1141-2. PMID: 31300002; PMCID: PMC6626409.

Long-term Medicine Use

Katusiime B, Corlett SA, Krska J. **Development and validation of a revised instrument to measure burden of long-term medicines use: the Living with Medicines Questionnaire version 3.** *Patient Relat Outcome Meas.* 2018 May 28;9:155-168. doi: 10.2147/PROM.S151143. PMID: 29881317; PMCID: PMC5978458.

Mood disorder

Sajatovic M, Thompson TR, Nanry K, Edwards S, Manjunath R. **Prospective, open-label trial measuring satisfaction and convenience of two formulations of lamotrigine in subjects with mood disorders.** Patient Prefer Adherence. 2013 May 7;7:411-7. doi: 10.2147/PPA.S40271. PMID: 23687443; PMCID: PMC3653756.

Multiple Chronic conditions

Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. **Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions.** BMC Med. 2012 Jul 4;10:68. doi: 10.1186/1741-7015-10-68. PMID: 22762722; PMCID: PMC3402984.

Multiple Sclerosis

Inshasi J, Farouk S, Shatila A, Hassan A, Szolics M, Thakre M, Kayed D, Krieger D, Almadani A, Alsaadi T, Benedetti B, Mifsud V, Jacob A, Sayegh S, Boshra A, Alroughani R. **Multicentre Observational Study of Treatment Satisfaction with Cladribine Tablets in the Management of Relapsing Multiple Sclerosis in the Arabian Gulf: The CLUE Study.** Neurol Ther. 2023 Aug;12(4):1309-1318. doi: 10.1007/s40120-023-00497-2. Epub 2023 Jun 8. PMID: 37289421; PMCID: PMC10310633.

Brochet B, Hupperts R, Langdon D, Solari A, Piehl F, Lechner-Scott J, Montalban X, Selmaj K, Valis M, Rejdak K, Havrdova EK, Patti F, Alexandri N, Nolting A, Keller B. **Treatment satisfaction, safety, and tolerability of cladribine tablets in patients with highly active relapsing multiple sclerosis: CLARIFY-MS study 6-month interim analysis.** Mult Scler Relat Disord. 2022 Jan;57:103385. doi: 10.1016/j.msard.2021.103385. Epub 2021 Nov 9. PMID: 35158476.

Wray S, Jacques F, Miller TA, Nicholas JA, Arroyo R, Travis L, Khatri B, Chirieac M, Gandhi R, Roesch N, Rodrigues A, Melas-Melt L, Rawlings AM, Hunter SF. **Satisfaction with alemtuzumab in relapsing multiple sclerosis patients: Results from the real-world PRO-ACT study.** Mult Scler J Exp Transl Clin. 2022 Nov 15;8(4):20552173221135888. doi: 10.1177/20552173221135888. PMID: 36407472; PMCID: PMC9669692.

Räuber S, Pawlitzki M, Korsen M, Kullmann JS, Thoene D, Pfeuffer S, Rolfes L, Nelke C, Melzer N, Ruck T, Meuth SG; INFUSE-MS study group. **A national, multi-center study in Germany to assess implementation of infusion management, treatment satisfaction and quality of life in MS patients receiving alemtuzumab.** Mult Scler Relat Disord. 2022 Mar;59:103670. doi: 10.1016/j.msard.2022.103670. Epub 2022 Feb 5. PMID: 35150978.

Tsivgoulis G, Deftereos S, Gobbi C, Gulowsen Celius E, Kulakowska A, Maniscalco G, Mendes I, Grigoriadis N. **Oral Cladribine in Patients who Change From First-Line Disease Modifying Treatments for Multiple Sclerosis: Protocol of a Prospective Effectiveness and Safety Study (CLAD CROSS).** J Cent Nerv Syst Dis. 2022 Apr 1;14:11795735211069441. doi: 10.1177/11795735211069441. PMID: 35392050; PMCID: PMC8980423.

Limmroth V, Bayer-Gersmann K, Mueller C, Schürks M. **Ascertaining Medication Use and Patient-Reported Outcomes via an App and Exploring Gamification in Patients With Multiple Sclerosis Treated With Interferon β -1b: Observational Study.** JMIR Form Res. 2022 Mar 14;6(3):e31972. doi: 10.2196/31972. Erratum in: JMIR Form Res. 2022 Mar 17;6(3):e38002. PMID: 35285806; PMCID: PMC8929528.

Álvarez-Rodríguez E, Sánchez-Franco CM, Pérez-Haro MJ, Bello-Otero L, Aguado-Valcarcel M, González-Suárez I. **Development of a scale for the evaluation of the quality of the shared decision process in multiple sclerosis patients.** PLoS One. 2022 May 13;17(5):e0268125. doi: 10.1371/journal.pone.0268125. PMID: 35560185; PMCID: PMC9106213.

Hoffmann FA, Trenova A, Llana MA, Fischer J, Lus G, von Bredow D, Lara N, Lam E, Van Hoef M, Bakshi R. **Patient satisfaction with ExtaviPro™ 30G, a new auto-injector for administering interferon β -1b in multiple sclerosis: results from a real-world, observational EXCHANGE study.** BMC Neurol. 2017 Aug 9;17(1):156. doi: 10.1186/s12883-017-0928-9. PMID: 28793876; PMCID: PMC5549369.



Boeru G, Milanov I, De Robertis F, Kozubski W, Lang M, Rojas-Farreras S, Tomlinson M. **ExtaviJect® 30G device for subcutaneous self-injection of interferon beta-1b for multiple sclerosis: a prospective European study.** *Med Devices (Auckl)*. 2013 Nov 15;6:175-84. doi: 10.2147/MDER.S52590. PMID: 24255602; PMCID: PMC3832381.

Calkwood J, Cree B, Crayton H, Kantor D, Steingo B, Barbato L, Hashmonay R, Agashivala N, McCague K, Tenenbaum N, Edwards K. **Impact of a switch to fingolimod versus staying on glatiramer acetate or beta interferons on patient- and physician-reported outcomes in relapsing multiple sclerosis: post hoc analyses of the EPOC trial.** *BMC Neurol*. 2014 Nov 26;14:220. doi: 10.1186/s12883-014-0220-1. PMID: 25424122; PMCID: PMC4253981.

Drulovic J, Cukic M, Grgic S, Dincic E, Raicevic R, Nadj C, Toncev G, Vojinovic S, Mesaros S, Kistic Tepavcevic D, Dujmovic I, Tadic D, Miletic-Drakulic S, Dackovic J, Kostic S, Erakovic J, Sakalas L, Savic D, Suknjaja V, Martinovic V, Maric G, Pekmezovic T. **The impact of betaplus program on patient treatment satisfaction with interferon beta-1b in multiple sclerosis: Multicentric cross-sectional survey in the western Balkan countries.** *Mult Scler Relat Disord*. 2017 Jan;11:56-61. doi: 10.1016/j.msard.2016.12.002. Epub 2016 Dec 8. PMID: 28104258.

Centonze D, Fantozzi R, Buttari F, Grimaldi LME, Totaro R, Corea F, Marrosu MG, Confalonieri P, Cottone S, Trojano M, Zipoli V. **Multicenter Interventional Phase IV Study for the Assessment of the Effects on Patient's Satisfaction of Peg IFN Beta-1a (Pre-filled Pen) in Subjects With Relapsing-Remitting Multiple Sclerosis Unsatisfied With Other Injectable Subcutaneous Interferons (PLATINUM Study).** *Front Neurol*. 2021 Apr 22;12:637615. doi: 10.3389/fneur.2021.637615. PMID: 33967938; PMCID: PMC8101263.

Patrick Vermersch, Jeremy Hobart, Catherine Dive-Pouletty, Sylvie Bozzi, Steven Hass and Patricia K Coyle. **Measuring treatment satisfaction in MS: Is the Treatment Satisfaction Questionnaire for Medication fit for purpose?** *Multiple Sclerosis Journal* 2017, Vol. 23(4): 604–613.

Turčáni P, Mašková J, Húska J. **Real-World Treatment Patterns of Disease Modifying Therapy (DMT) for Patients with Relapse-Remitting Multiple Sclerosis and Patient Satisfaction with Therapy: Results of the Non-Interventional SKARLET Study in Slovakia.** *Patient Prefer Adherence*. 2020 Jul 7;14:1129-1135. doi: 10.2147/PPA.S254427. PMID: 32753853; PMCID: PMC7354948.

Schriefer D, Haase R, Kullmann JS, Ziemssen T. **Health-Related Quality of Life and the Relationship to Treatment Satisfaction in Patients with Multiple Sclerosis: Insights from a Large Observational Study.** *Patient Prefer Adherence*. 2020 May 22;14:869-880. doi: 10.2147/PPA.S248272. PMID: 32546981; PMCID: PMC7250312.

Lanzillo R, Sparaco M, Lavorgna L, Carmisciano L, Signoriello E, Signori A, Costabile T, Maniscalco GT, Saccà F, Cepparulo S, Russo CV, Bisecco A, Frattaruolo N, Strianese A, Lus G, Brescia Morra V, Bonavita S. **A snapshot on patient-reported outcome measures of people with multiple sclerosis on first-line therapies in a real world setting.** *Neurol Sci*. 2020 Nov;41(11):3235-3241. doi: 10.1007/s10072-020-04367-9. Epub 2020 May 10. PMID: 32388646.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Poole EM, Robinson M, Gold R. **Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study.** *Mult Scler Relat Disord*. 2019 Jun;31:157-164. doi: 10.1016/j.msard.2019.03.022. Epub 2019 Mar 30. PMID: 31005729.

Kallmann BA, Tiel-Wilck K, Kullmann JS, Engelmann U, Chan A. **Real-life outcomes of teriflunomide treatment in patients with relapsing multiple sclerosis: TAURUS-MS observational study.** *Ther Adv Neurol Disord*. 2019 Mar 27;12:1756286419835077. doi: 10.1177/1756286419835077. PMID: 30944584; PMCID: PMC6437319.

Guger M, Ackerl MM, Heine M, Hofinger-Renner C, Spiss HK, Taut A, Unger K, Leutmezer F. **Favorable benefit-risk ratio with teriflunomide treatment in relapsing-remitting multiple sclerosis: Results of the 2-year, multicenter, prospective, noninterventional TAURUS MS study in Austria.** *eNeurologicalSci*. 2022 Mar 7;27:100396. doi: 10.1016/j.ensci.2022.100396. PMID: 35295745; PMCID: PMC8919225.



Hestvik ALK, Frederiksen JL, Nielsen HH, Torkildsen Ø, Eek C, Huang-Link Y, Haghighi S, Tsai JA, Kant M. **Real-world study of relapsing-remitting multiple sclerosis patients treated with Teriflunomide in Nordic countries: Quality-Of-Life, efficacy, safety and adherence outcomes.** *Mult Scler Relat Disord.* 2022 Jul;63:103892. doi: 10.1016/j.msard.2022.103892. Epub 2022 May 16. PMID: 35696880.

Dardiotis E, Perpati G, Borsos M, Nikolaidis I, Tzanetakos D, Deretzi G, Koutlas E, Kilidireas C, Mitsikostas DD, Hadjigeorgiou G, Grigoriadis N; AURELIO investigators. **Real-World Assessment of Quality of Life in Patients with Relapsing Remitting Multiple Sclerosis Treated with Teriflunomide for Two Years: Patient-Reported Outcomes from the AURELIO Study in Greece.** *Neurol Ther.* 2022 Jul 13. doi: 10.1007/s40120-022-00384-2. Epub ahead of print. PMID: 35829919.

Hendin B, Naismith RT, Wray SE, Huang D, Dong Q, Livingston T, Jones DL, Watson C, Jhaveri M. **Treatment satisfaction significantly improves in patients with multiple sclerosis switching from interferon beta therapy to peginterferon beta-1a every 2 weeks.** *Patient Prefer Adherence.* 2018 Jul 20;12:1289-1297. doi: 10.2147/PPA.S157317. PMID: 30050291; PMCID: PMC6056153.

Mékiès C, Heinzlef O, Jenny B, Ramelli AL, Clavelou P. **Treatment satisfaction and quality of life in patients treated with fingolimod.** *Patient Prefer Adherence.* 2018 May 22;12:899-907. doi: 10.2147/PPA.S144021. PMID: 29872275; PMCID: PMC5973401.

Hao J, Pitcavage J, Jones JB, Hoegerl C, Graham J. **Measuring Adherence and Outcomes in the Treatment of Patients With Multiple Sclerosis.** *J Am Osteopath Assoc.* 2017 Dec 1;117(12):737-747. doi: 10.7556/jaoa.2017.145. PMID: 29181516.

Eagle T, Stuart F, Chua AS, LaRussa A, Leclaire K, Cook SL, Chitnis T, Weiner HL, Glanz BI, Healy BC. **Treatment satisfaction across injectable, infusion, and oral disease-modifying therapies for multiple sclerosis.** *Mult Scler Relat Disord.* 2017 Nov;18:196-201. doi: 10.1016/j.msard.2017.10.002. Epub 2017 Oct 5. PMID: 29141809.

Coyle PK, Khatri B, Edwards KR, Meca-Lallana JE, Cavalier S, Rufi P, Benamor M, Brette S, Robinson M, Gold R; Teri-PRO Trial Group. **Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study.** *Mult Scler Relat Disord.* 2017 Oct;17:107-115. doi: 10.1016/j.msard.2017.07.006. Epub 2017 Jul 6. PMID: 29055438.

Fernández O, Duran E, Ayuso T, Hernández L, Bonaventura I, Forner M; STICK Study Investigators Group. **Treatment satisfaction with injectable disease-modifying therapies in patients with relapsing-remitting multiple sclerosis (the STICK study).** *PLoS One.* 2017 Oct 19;12(10):e0185766. doi: 10.1371/journal.pone.0185766. PMID: 29049356; PMCID: PMC5648132.

Vermersch P, Czlonkowska A, Grimaldi LM, Confavreux C, Comi G, Kappos L, Olsson TP, Benamor M, Bauer D, Truffinet P, Church M, Miller AE, Wolinsky JS, Freedman MS, O'Connor P; TENERE Trial Group. **Teriflunomide versus subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial.** *Mult Scler.* 2014 May;20(6):705-16. doi: 10.1177/1352458513507821. Epub 2013 Oct 14. PMID: 24126064.

Saiz A, Mora S, Blanco J; en representación de los investigadores del estudio COMPLIANCE. **Therapeutic compliance of first line disease-modifying therapies in patients with multiple sclerosis. COMPLIANCE Study.** *Neurologia.* 2015 May;30(4):214-22. English, Spanish. doi: 10.1016/j.nrl.2013.12.008. Epub 2014 Jan 28. PMID: 24484756.

Hardy TA, Parratt J, Beadnall H, Blum S, Macdonell R, Beran RG, Shuey N, Lee A, Carroll W, Shaw C, Worrell R, Moody J, Sedhom M, Barnett M, Vucic S. **Treatment satisfaction in patients with relapsing-remitting multiple sclerosis initiated on teriflunomide in routine clinical practice: Australian observational data.** *BMJ Neurol Open.* 2022 Jul 4;4(2):e000315. doi: 10.1136/bmjno-2022-000315. PMID: 35865788; PMCID: PMC9255404.

Muscular atrophy

Osmanovic A, Ranxha G, Kumpe M, Wurster CD, Stolte B, Cordts I, Günther R, Freigang M, Müschen LH, Binz C, Hermann A, Deschauer M, Lingor P, Ludolph AC, Hagenacker T, Schreiber-Katz O, Petri S. **Treatment satisfaction in 5q-spinal muscular atrophy under nusinersen therapy.** *Ther Adv Neurol Disord.* 2021 Mar 5;14:1756286421998902. doi: 10.1177/1756286421998902. PMID: 33747131; PMCID: PMC7940734.



Myasthenia Gravis

Beecher G, Anderson D, Siddiqi ZA. **Subcutaneous immunoglobulin in myasthenia gravis exacerbation: A prospective, open-label trial.** *Neurology*. 2017 Sep 12;89(11):1135-1141. doi: 10.1212/WNL.0000000000004365. Epub 2017 Aug 16. PMID: 28814461.

Neuralgia

Serpell M, Gater A, Carroll S, Abetz-Webb L, Mannan A, Johnson R. **Burden of post-herpetic neuralgia in a sample of UK residents aged 50 years or older: findings from the Zoster Quality of Life (ZQOL) study.** *Health Qual Life Outcomes*. 2014 Jun 11;12:92. doi: 10.1186/1477-7525-12-92. PMID: 24920439; PMCID: PMC4063222.

Osteoarthritis

Ueda K, Sasaki N, Goren A, Calhoun SR, Shinjo K, Enomoto H, Muneta T. **Treatment satisfaction with pharmaceutical interventions in Japanese adults with osteoarthritis and chronic knee pain: an analysis of a web-based survey.** *Clin Interv Aging*. 2018 Oct 26;13:2179-2191. doi: 10.2147/CIA.S176289. PMID: 30464427; PMCID: PMC6211312.

Huang WN, Tso TK. **Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.** *Bosn J Basic Med Sci*. 2018 Feb 20;18(1):87-94. doi: 10.17305/bjbm.2017.2214. PMID: 28954205; PMCID: PMC5826680.

Xue Q, Long H, Lin J, Du D, Zhou J, Chen J, Li S, Zhang Y, Cheng Y, Ma X, Zhang Z. **Quality of life and treatment satisfaction with pharmacological interventions in Chinese adults with chronic pain due to osteoarthritis.** *BMC Musculoskelet Disord*. 2021 Feb 13;22(1):178. doi: 10.1186/s12891-021-04012-2. PMID: 33583400; PMCID: PMC7882067.

Opioid Related

Lintzeris N, Dunlop AJ, Haber PS, Lubman DI, Graham R, Hutchinson S, Arunogiri S, Hayes V, Hjelmström P, Svedberg A, Peterson S, Tiberg F. **Patient-Reported Outcomes of Treatment of Opioid Dependence With Weekly and Monthly Subcutaneous Depot vs Daily Sublingual Buprenorphine: A Randomized Clinical Trial.** *JAMA Netw Open*. 2021 May 3;4(5):e219041. doi: 10.1001/jamanetworkopen.2021.9041. PMID: 33970256; PMCID: PMC8111483.

Gupta S, Patel H, Scopel J, Mody RR. **Impact of constipation on opioid therapy management among long-term opioid users, based on a patient survey.** *J Opioid Manag*. 2015 Jul-Aug;11(4):325-38. doi: 10.5055/jom.2015.0282. PMID: 26312960.

Osteoporosis

Byun DW, Moon SH, Kim T, Lee HH, Park HM, Kang MI, Ha YC, Chung HY, Yoon BK, Kim TY, Chae SU, Shin CS, Yang KH, Lee JH, Chang JS, Kim SH, Kim IJ, Koh JM, Jung JH, Yi KW, Yoo JJ, Chung DJ, Lee YK, Yoon HK, Hong S, Kim DY, Baek KH, Kim HJ, Kim YJ, Kang S, Min YK. **Assessment of patient-reported outcomes (PROs): treatment satisfaction, medication adherence, and quality of life (QoL) and the associated factors in postmenopausal osteoporosis (PMO) patients in Korea.** *J Bone Miner Metab*. 2019 May;37(3):563-572. doi: 10.1007/s00774-018-0956-6. Epub 2018 Sep 20. PMID: 30238428.

Reynolds K, Viswanathan HN, O'Malley CD, Muntner P, Harrison TN, Cheetham TC, Hsu JW, Gold DT, Silverman S, Grauer A, Morisky DE. **Psychometric properties of the Osteoporosis-specific Morisky Medication Adherence Scale in postmenopausal women with osteoporosis newly treated with bisphosphonates.** *Ann Pharmacother*. 2012 May;46(5):659-70. doi: 10.1345/aph.1Q652. Epub 2012 Apr 17. PMID: 22510666.



Paediatrics

A. Trama & Y. Kodra & D. Taruscio. **Final report on unmet needs for RD (including recommendations to guarantee effective and equal availability of drugs for RD throughout Europe).** TEDDY TASK-FORCE IN EUROPE FOR DRUG DEVELOPMENT FOR THE YOUNG. 2008.

Susan E. Creary, MD, MSc, Mark T. Gladwin, MD, Melissa Byrne, MPH, RN, Mariana Hildesheim, MS, and Lakshmanan Krishnamurti, MD. **A Pilot Study of Electronic Directly Observed Therapy to Improve Hydroxyurea Adherence in Pediatric Patients With Sickle-Cell Disease.** *Pediatr Blood Cancer* 2014; 61:1068–1073.

Regnault A, et al, **Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis.** *J Cyst Fibros* (2012).

Baaleman DF, Wegh CAM, Hoogveld MTA, Benninga MA, Koppen IJN. **Transanal Irrigation in Children: Treatment Success, Quality of Life, Adherence, Patient Experience and Independence.** *J Pediatr Gastroenterol Nutr.* 2022 Jun 7. doi: 10.1097/MPG.0000000000003515. Epub ahead of print. PMID: 35675698.

Koppen IJN, van Wassenae EA, Barendsen RW, Brand PL, Benninga MA. **Adherence to Polyethylene Glycol Treatment in Children with Functional Constipation Is Associated with Parental Illness Perceptions, Satisfaction with Treatment, and Perceived Treatment Convenience.** *J Pediatr.* 2018 Aug;199:132-139.e1. doi: 10.1016/j.jpeds.2018.03.066. Epub 2018 May 10. PMID: 29754864.

Peripheral Neuropathic Pain

Perrot S, Lantéri-Minet M. **Patients' Global Impression of Change in the management of peripheral neuropathic pain: Clinical relevance and correlations in daily practice.** *Eur J Pain.* 2019 Jul;23(6):1117-1128. doi: 10.1002/ejp.1378. Epub 2019 Mar 18. PMID: 30793414.

Viel E, Eerdeken M, Kandaswamy P. **Treatment Impact on Patient-Reported Outcomes in Peripheral Neuropathic Pain: Comparing Single Intervention With Topical High-Concentration Capsaicin to Daily Oral Pregabalin.** *Pain Physician.* 2021 Sep;24(6):453-463. PMID: 34554688.

Plaque Psoriasis

Fink C, Alt C, Schank TE, Sies K, Kilian S, Schäkel K. **Multiarm study comparing patient-reported and clinical outcome measures in patients undergoing antipsoriatic therapy with non-biological systemic agents in a real-world setting.** *J Dermatolog Treat.* 2022 Nov;33(7):2997-3004. doi: 10.1080/09546634.2022.2095329. Epub 2022 Jul 4. PMID: 35763015.

Velasco M, González-Fernández D, Rodríguez-Martín M, Sánchez-Regaña M, Pérez-Barrio S. **Patient and Physician Satisfaction with Calcipotriol and Betamethasone Dipropionate Aerosol Foam in the Treatment of Plaque Psoriasis on the Body.** *Actas Dermosifiliogr.* 2019 Nov;110(9):752-758. English, Spanish. doi: 10.1016/j.ad.2019.03.013. Epub 2019 Jun 27. PMID: 31256797.
Imafuku S, Ohata C, Okubo Y, Tobita R, Saeki H, Mabuchi T, Hashimoto Y, Murotani K, Kitabayashi H, Kanai Y. **Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: The ProLOGUE study.** *J Dermatol Sci.* 2022 Mar;105(3):176-184. doi: 10.1016/j.jdermsci.2022.02.007. Epub 2022 Feb 15. PMID: 35248465.

Aljaser M, Amar L, Kircik LH. **Use of Apremilast in Patients Who Are Dissatisfied With Stable Maintenance Topical Therapy.** *J Drugs Dermatol.* 2019 Apr 1;18(4):336-340. PMID: 31012561.

Gupta S, Garbarini S, Nazareth T, Khilfeh I, Costantino H, Kaplan D. **Characterizing Outcomes and Unmet Needs Among Patients in the United States with Mild-to-Moderate Plaque Psoriasis Using Prescription Topicals.** *Dermatol Ther (Heidelb).* 2021 Dec;11(6):2057-2075. doi: 10.1007/s13555-021-00620-x. Epub 2021 Oct 14. PMID: 34648148; PMCID: PMC8514608.

Fowler JF, Del Rosso JQ, Pakunlu RI, Sidgiddi S. **Treatment Satisfaction, Product Perception, and Quality of Life in Plaque Psoriasis Patients Using Betamethasone Dipropionate Spray 0.05.** *J Clin Aesthet Dermatol.* 2017 Nov;10(11):13-18. Epub 2017 Nov 1. Erratum in: *J Clin Aesthet Dermatol.* 2018 Oct;11(10):13. PMID: 29399255; PMCID: PMC5774905.



Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M. **Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.** J Cutan Med Surg. 2012 Nov-Dec;16(6):407-16. doi: 10.1177/120347541201600609. PMID: 23149196.

Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R. **Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.** Dermatol Pract Concept. 2021 May 20;11(3):e2021056. doi: 10.5826/dpc.1103a56. PMID: 34123560; PMCID: PMC8172017.

Postamputation Pain

Knezevic NN, Aijaz T, Candido KD, Kovaleva S, Lissounov A, Knezevic I. **The Effect of Once-Daily Gabapentin Extended Release Formulation in Patients With Postamputation Pain.** Front Pharmacol. 2019 May 15;10:504. doi: 10.3389/fphar.2019.00504. PMID: 31156433; PMCID: PMC6529536.

Postmenopause

Palacios S, Ramirez M, Lilue M. **Clinical study of the tolerability of calcium carbonate-casein microcapsules as a dietary supplement in a group of postmenopausal women.** Drugs Context. 2020 Apr 23;9:2020-1-4. doi: 10.7573/dic.2020-1-4. PMID: 32362931; PMCID: PMC7185908.

Palacios S, Agodoa I, Bonnick S, Van den Bergh JP, Ferreira I, Ho PR, Brown JP. **Treatment satisfaction in postmenopausal women suboptimally adherent to bisphosphonates who transitioned to denosumab compared with risedronate or ibandronate.** J Clin Endocrinol Metab. 2015 Mar;100(3):E487-92. doi: 10.1210/jc.2014-3594. Epub 2014 Dec 16. PMID: 25514106.

Barrett-Connor E, Wade SW, Do TP, Satram-Hoang S, Stewart R, Gao G, Macarios D. **Treatment satisfaction and persistence among postmenopausal women on osteoporosis medications: 12-month results from POSSIBLE US™.** Osteoporos Int. 2012 Feb;23(2):733-41. doi: 10.1007/s00198-011-1620-3. Epub 2011 Apr 6. PMID: 21625886

Psoriasis

Honma M, Kanai Y, Murotani K, Ito K, Ohata C, Yamazaki F, Saeki H, Seishima M, Mizutani Y, Kitabayashi H, Imafuku S. **Effectiveness of brodalumab in improving itching and skin pain in Japanese patients with psoriasis: The ProLOGUE study.** J Dermatol. 2022 Dec 20. doi: 10.1111/1346-8138.16682. Epub ahead of print. PMID: 36540010.

Kornmehl H, Callis Duffin K, Salame N, Perez-Chada LM, Singh S, Garg A, Gottlieb AB, Latella J, Merola JF, Armstrong AW. **Examination of Treatment Satisfaction Instruments in Psoriasis: 2017 Results from the Psoriasis Working Group of the International Dermatology Outcome Measures (IDEOM).** Dermatology. 2020 Jan 28:1-7. doi: 10.1159/000501582. Epub ahead of print. PMID: 31991410.

Abdshah A, Parsaeian M, Nasimi M, Ghiasi M. **Validating the "Treatment Satisfaction Questionnaire for Medication" in Persian, and Evaluating Treatment Satisfaction Among Patients With Psoriasis.** Value Health Reg Issues. 2021 Nov 17;29:16-20. doi: 10.1016/j.vhri.2021.06.008. Epub ahead of print. PMID: 34800824.

Fink C, Alt C, Schank TE, Sies K, Kilian S, Schäkel K. **Multiarm study comparing patient-reported and clinical outcome measures in patients undergoing antipsoriatic therapy with non-biological systemic agents in a real-world setting.** J Dermatolog Treat. 2022 Jul 4:1-8. doi: 10.1080/09546634.2022.2095329. Epub ahead of print. PMID: 35763015.



Driessen RJ, Bisschops LA, Adang EM, Evers AW, Van De Kerkhof PC, De Jong EM. **The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics.** Br J Dermatol. 2010 Jun;162(6):1324-9. doi: 10.1111/j.1365-2133.2010.09693.x. Epub 2010 Feb 15. PMID: 20163420.

van der Schoot LS, van den Reek JMPA, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM, Mommers JM, Koetsier MIA, Berends MAM, Arnold WP, Peters B, Andriessen MPM, Den Hengst CW, Kuijpers ALA, de Jong EMGJ. **Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective BioCAPTURE registry.** J Eur Acad Dermatol Venereol. 2019 Oct;33(10):1913-1920. doi: 10.1111/jdv.15733. Epub 2019 Jul 7. PMID: 31177583.

van den Reek JM, van Lüumig PP, Otero ME, Zweegers J, van de Kerkhof PC, Ossenkoppele PM, Njoo MD, Mommers JM, Koetsier MI, Arnold WP, Sybrandy-Fleuren BA, Kuijpers AL, Andriessen MP, Seyger MM, Kievit W, de Jong EM. **Satisfaction of treatment with biologics is high in psoriasis: results from the Bio-CAPTURE network.** Br J Dermatol. 2014 May;170(5):1158-65. doi: 10.1111/bjd.12862. Erratum in: Br J Dermatol. 2014 Jun;170(6):1382. PMID: 24484403.

Bagel J, Zapata J, Nelson E. **A Prospective, Open-Label Study Evaluating Adjunctive Calcipotriene 0.005%/Betamethasone Dipropionate 0.064% Foam in Psoriasis Patients With Inadequate Response to Biologic Therapy.** J Drugs Dermatol. 2018 Aug 1;17(8):845-850. PMID: 30124723.

Bagel J, Levi E, Tyring S, Knuckles ML. **Real-life treatment profile of calcipotriene and betamethasone dipropionate topical suspension in patients with psoriasis vulgaris.** J Drugs Dermatol. 2014 Nov;13(11):1374-9. PMID: 25607705.

Ichiyama S, Ito M, Funasaka Y, Abe M, Nishida E, Muramatsu S, Nishihara H, Kato H, Morita A, Imafuku S, Saeki H. **Assessment of medication adherence and treatment satisfaction in Japanese patients with psoriasis of various severities.** J Dermatol. 2018 Jun;45(6):727-731. doi: 10.1111/1346-8138.14225. Epub 2018 Jan 21. Erratum in: J Dermatol. 2018 Jun;45(6):751. PMID: 29356075.

Imafuku S, Kanai Y, Murotani K, Nomura T, Ito K, Ohata C, Yamazaki F, Miyagi T, Takahashi H, Okubo Y, Saeki H, Honma M, Tada Y, Mabuchi T, Higashiyama M, Kobayashi S, Hashimoto Y, Seishima M, Kakuma T. **Utility of the Dermatology Life Quality Index at initiation or switching of biologics in real-life Japanese patients with plaque psoriasis: Results from the ProLOGUE study.** J Dermatol Sci. 2021 Mar;101(3):185-193. doi: 10.1016/j.jdermsci.2021.01.002. Epub 2021 Jan 7. PMID: 33495058.

Schaarschmidt ML, Kromer C, Herr R, Schmieder A, Goerdts S, Peitsch WK. **Treatment satisfaction of patients with psoriasis.** Acta Derm Venereol. 2015 May;95(5):572-8. doi: 10.2340/00015555-2011. PMID: 25394584.

Papp KA, Barber K, Bissonnette R, Bourcier M, Lynde CW, Poulin Y, Shelton J, Garces K, Toole J, Poulin-Costello M. **Improvements in patient-reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE.** J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1555-61. doi: 10.1111/jdv.12934. Epub 2015 Jan 21. PMID: 25611084; PMCID: PMC5024053.

Klein TM, Blome C, Kleyn CE, Conrad C, Sator PG, Stähle M, Eyerich K, Radtke MA, Bundy C, Cordey M, Griffiths CEM, Augustin M. **Real-World Experience of Patient-Relevant Benefits and Treatment Satisfaction with Apremilast in Patients with Psoriasis: An Analysis of the APPRECIATE Study.** Dermatol Ther (Heidelb). 2021 Nov 23. doi: 10.1007/s13555-021-00628-3. Epub ahead of print. PMID: 34813044.

Campanati A, Atzori L, Potenza C, Damiani G, Bianchi L, Corazza M, Tiberio R, Prignano F, Argenziano G, Fargnoli MC, Stingeni L, Mazzotta A, De Pità O, Mazzatenta C, Feliciani C, Donini M, Offidani A, Peris K; LION study group. **Patient satisfaction with calcipotriol/betamethasone dipropionate cutaneous foam for the treatment of plaque psoriasis: The LION real-life multicenter prospective observational cohort study.** Dermatol Ther. 2021 Sep;34(5):e15077. doi: 10.1111/dth.15077. Epub 2021 Aug 9. PMID: 34333823.

Pulmonary arterial hypertension

Chen H, Rosenzweig EB, Gotzkowsky SK, Arneson C, Nelsen AC, Bourge RC. **Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension.** *Health Qual Life Outcomes.* 2013 Mar 6;11:31. doi: 10.1186/1477-7525-11-31. PMID: 23496856; PMCID: PMC3610124.

Yuichi Tamura, Tomohiko Ono, Keiichi Fukuda, Toru Satoh, Shigetake Sasayama. **Evaluation of a New Formulation of Epoprostenol Sodium in Japanese Patients with Pulmonary Arterial Hypertension (EPITOME4).** *Adv Ther* (2013) 30:459–471.

Review of Psychometric Properties

Joan Trujols, MSc, Ioseba Iraurgi, PhD, Nuria Sinol, MSc, Maria J. Portella, PhD, Victor Perez, MD, PhD, and Jose Perez de los Cobos, MD, PhD. **Satisfaction With Methadone as a Medication Psychometric Properties of the Spanish Version of the Treatment Satisfaction Questionnaire for Medication.** *J Clin Psychopharmacol* 2012;32: 69-74.

Rheumatoid Arthritis

Jobanputra P, Maggs F, Deeming A, et al. **A randomised efficacy and discontinuation study of etanercept versus adalimumab (RED SEA) for rheumatoid arthritis: a pragmatic, unblinded, non-inferiority study of first TNF inhibitor use: outcomes over 2 years.** *BMJ Open* 2012;2.

Kawahito Y, Takakubo Y, Morinobu A, Matsubara N, Nagy O, Sugiyama E. **Patient satisfaction, preferences, expectations, characteristics, and impact of suboptimal control of rheumatoid arthritis: A subgroup analysis of Japanese patients from a large international cohort study (SENSE).** *PLoS One.* 2021 Nov 15;16(11):e0259389. doi: 10.1371/journal.pone.0259389. PMID: 34780502; PMCID: PMC8592402.

Lee YC, Lu F, Colls J, Luo D, Wang P, Dunlop DD, Muhammad LN, Song J, Michaud K, Solomon DH. **Outcomes of a Mobile App to Monitor Patient-Reported Outcomes in Rheumatoid Arthritis: A Randomized Controlled Trial.** *Arthritis Rheumatol.* 2021 Aug;73(8):1421-1429. doi: 10.1002/art.41686. Epub 2021 Jun 18. PMID: 33559338; PMCID: PMC8330418.

Jiang N, Yang P, Liu S, Li H, Wu L, Shi X, Fang Y, Zhao Y, Xu J, Jiang Z, Wu Z, Duan X, Wang Q, Tian X, Li M, Zeng X. **Satisfaction of Patients and Physicians with Treatments for Rheumatoid Arthritis: A Population-Based Survey in China.** *Patient Prefer Adherence.* 2020 Jun 23;14:1037-1047. doi: 10.2147/PPA.S232578. PMID: 32606620; PMCID: PMC7320887.

Sidiropoulos P, Bounas A, Athanassiou P, Koutsianas C, Petrikkou E, Kaltsonoudis E, Drosos A, Vassilopoulos D. **Correlation of patient preferences to treatment outcomes in patients with rheumatoid arthritis treated with tumour necrosis factor inhibitors in Greece.** *Clin Rheumatol.* 2020 May 26. doi: 10.1007/s10067-020-05171-8. Epub ahead of print. PMID: 32458235.

Radawski C, Genovese MC, Hauber B, Nowell WB, Hollis K, Gaich CL, DeLozier AM, Gavigan K, Reynolds M, Cardoso A, Curtis JR. **Patient Perceptions of Unmet Medical Need in Rheumatoid Arthritis: A Cross-Sectional Survey in the USA.** *Rheumatol Ther.* 2019 Sep;6(3):461-471. doi: 10.1007/s40744-019-00168-5. Epub 2019 Aug 6. PMID: 31385264; PMCID: PMC6702617.

Taylor PC, Ancuta C, Nagy O, de la Vega MC, Gordeev A, Janková R, Kalyoncu U, Lagunes-Galindo I, Morović-Vergles J, de Souza MPGUES, Rojkovich B, Sidiropoulos P, Kawakami A. **Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in a Large International Rheumatoid Arthritis Cohort: SENSE Study.** *Patient Prefer Adherence.* 2021 Feb 17;15:359-373. doi: 10.2147/PPA.S289692. PMID: 33633444; PMCID: PMC7900444.

Sidiropoulos P, Bounas A, Galanopoulos N, Vosvotekas G, Koukli EM, Georgiou P, Marketos N, Antachopoulou T, Kyriakakis A, Koronaïou M. **Treatment Satisfaction, Patient Preferences, and the Impact of Suboptimal Disease Control in Rheumatoid Arthritis Patients in Greece: Analysis of the Greek Cohort of SENSE study.** *Mediterr J Rheumatol.* 2022 Mar 31;33(1):14-34. doi: 10.31138/mjr.33.1.14. PMID: 35611113; PMCID: PMC9092106.

Abu Hamdeh H, Al-Jabi SW, Koni A, Zyoud SH. **Health-related quality of life and treatment satisfaction in Palestinians with rheumatoid arthritis: a cross-sectional study.** BMC Rheumatol. 2022 Apr 6;6(1):19. doi: 10.1186/s41927-022-00251-5. PMID: 35382894; PMCID: PMC8985358.

Routine Clinical Practice

Hanna Norrlid, Jenny M. Norlin, Heidi Holmstrup, Irena Malmberg, Karin Sartorius, Henrik Thormann, Gregor B. E. Jemec & Gunnel Ragnarson Tennvall (2018) **Patient-reported outcomes in topical field treatment of actinic keratosis in Swedish and Danish patients,** *Journal of Dermatological Treatment*, 29:1, 68-73.

Schizophrenia

Fujikawa M, et al, **Evaluation of subjective treatment satisfaction with antipsychotics in schizophrenia patients,** *Prog Neuropsychopharmacol Biol Psychiatry* (2008).

Torrecilla-Olavarrieta R, Pérez-Revuelta J, García-Spínola E, López Martín Á, Mongil-SanJuan JM, Rodríguez-Gómez C, Villagrán-Moreno JM, González-Saiz F. **Satisfaction with antipsychotics as a medication: the role of therapeutic alliance and patient-perceived participation in decision making in patients with schizophrenia spectrum disorder.** *Int J Psychiatry Clin Pract.* 2020 Aug 13:1-9. doi: 10.1080/13651501.2020.1804942. Epub ahead of print. PMID: 32787650.

Fernández-Miranda JJ, Díaz-Fernández S, De Berardis D, López-Muñoz F. **Paliperidone Palmitate Every Three Months (PP3M) 2-Year Treatment Compliance, Effectiveness and Satisfaction Compared with Paliperidone Palmitate-Monthly (PP1M) in People with Severe Schizophrenia.** *J Clin Med.* 2021 Apr 1;10(7):1408. doi: 10.3390/jcm10071408. PMID: 33915786; PMCID: PMC8036785.

Petrić D, Rački V, Gačo N, Kaštelan A, Graovac M. **Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.** *J Child Adolesc Psychopharmacol.* 2019 Apr;29(3):197-204. doi: 10.1089/cap.2018.0044. Epub 2019 Feb 13. PMID: 30758986.

Bozzatello P, Bellino S, Mancini I, Sandei L, Zanalda E, Rocca P. **Effects on Satisfaction and Service Engagement of Paliperidone Palmitate Compared with Oral Paliperidone in Patients with Schizophrenia: An Open Label Randomized Controlled Trial.** *Clin Drug Investig.* 2019 Feb;39(2):169-178. doi: 10.1007/s40261-018-0734-1. PMID: 30523522.

Pérez-Revuelta J, Villagrán-Moreno JM, Moreno-Sánchez L, Pascual-Paño JM, González-Saiz F. **Patient perceived participation in decision making on their antipsychotic treatment: Evidence of validity and reliability of the COMRADE scale in a sample of schizophrenia spectrum disorders.** *Patient Educ Couns.* 2018 Aug;101(8):1477-1482. doi: 10.1016/j.pec.2018.03.018. Epub 2018 Mar 23. PMID: 29606551.

Vernon MK, Revicki DA, Awad AG, Dirani R, Panish J, Canuso CM, Grinspan A, Mannix S, Kalali AH. **Psychometric evaluation of the Medication Satisfaction Questionnaire (MSQ) to assess satisfaction with antipsychotic medication among schizophrenia patients.** *Schizophr Res.* 2010 May;118(1-3):271-8. doi: 10.1016/j.schres.2010.01.021. Epub 2010 Feb 20. PMID: 20172695.

Sweileh WM, Ihbesheh MS, Jarar IS, Sawalha AF, Abu Taha AS, Zyoud SH, Morisky DE. **Differences in medication adherence, satisfaction and clinical symptoms in schizophrenic outpatients taking different antipsychotic regimens.** *Curr Drug Saf.* 2011 Nov 1;6(5):285-90. doi: 10.2174/157488611798918755. PMID: 22424535.

Sweileh WM, Ihbesheh MS, Jarar IS, Sawalha AF, Abu Taha AS, Zyoud SH, Morisky DE. **Antipsychotic medication adherence and satisfaction among Palestinian people with schizophrenia.** *Curr Clin Pharmacol.* 2012 Feb 1;7(1):49-55. doi: 10.2174/157488412799218761. PMID: 22299769.

Spinal Muscular Atrophy

Meyer T, Maier A, Uzelac Z, Hagenacker T, Günther R, Schreiber-Katz O, Weiler M, Steinbach R, Weyen U, Koch JC, Kettemann D, Norden J, Dorst J, Wurster C, Ludolph AC, Stolte B, Freigang M, Osmanovic A, Petri S, Grosskreutz J, Rödiger A, Griep R, Gaudlitz M, Walter B, Münch C, Spittel S. **Treatment expectations and perception of therapy in adult patients with spinal muscular atrophy receiving nusinersen.** *Eur J Neurol.* 2021 Aug;28(8):2582-2595. doi: 10.1111/ene.14902. Epub 2021 Jun 16. PMID: 33960080.

Transplant

Alkatheri AA, Albekairy AM, Jarab A, Bustami R, Khalidi N, Alshaya A, Bin Saleh K, Alraddadi S, Alharbi S, Vasudevan S, Alsayyari A, Qandil AM. **Medication Adherence and Treatment Satisfaction Among Renal Transplant Recipients.** *Ann Transplant.* 2016 May 5;21:270-8. doi: 10.12659/aot.897101. PMID: 27147505.

Albekairy AM, Alkatheri AM, Jarab A, Khalidi N, Althiab K, Alshaya A, Saleh KB, Ismail WW, Qandil AM. **Adherence and treatment satisfaction in liver transplant recipients.** *Saudi J Gastroenterol.* 2016 Mar-Apr;22(2):127-32. doi: 10.4103/1319-3767.164209. PMID: 26997219; PMCID: PMC4817296.

Roche B, Bauhofer A, Gomez Bravo MÃ, Pageaux GP, Zoulim F, Otero A, Prieto M, Baliellas C, Samuel D. **Long-Term Effectiveness, Safety, and Patient-Reported Outcomes of Self-Administered Subcutaneous Hepatitis B Immunoglobulin in Liver Post-Transplant Hepatitis B Prophylaxis: A Prospective Non-Interventional Study.** *Ann Transplant.* 2022 May 10;27:e936162. doi: 10.12659/AOT.936162. PMID: 35534995; PMCID: PMC9107284.

Thromboembolism

Peidro-Garcés L, Otero-Fernandez R, Lozano-Lizarraga L. **Adherencia y satisfacción en la profilaxis antitrombótica ambulatoria oral frente a la parenteral: estudio SALTO [Adherence to and satisfaction with oral outpatient thromboembolism prophylaxis compared to parenteral: SALTO study].** *Rev Esp Cir Ortop Traumatol.* 2013 Jan-Feb;57(1):53-60. Spanish. doi: 10.1016/j.recot.2012.10.009. Epub 2012 Dec 5. PMID: 23594983.

Ulcerative Colitis

Peyrin-Biroulet L, Van Assche G, Sturm A, Gisbert JP, Gaya DR, Bokemeyer B, Mantzaris GJ, Armuzzi A, Sebastian S, Lara N, Lynam M, Rojas-Farreras S, Fan T, Ding Q, Black CM, Kachroo S. **Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study.** *Dig Liver Dis.* 2016 Jun;48(6):601-7. doi: 10.1016/j.dld.2016.01.013. Epub 2016 Mar 2. PMID: 27012447.

Gatopoulou A, Christodoulou DK, Katsanos KH, Bakos D, Mouzas I, Tzouvala M, Theodoropoulou A, Paspatis G, Theocharis G, Thomopoulos K, Giouleme O, Kourikou A, Manolakopoulos S, Zampeli E, Michopoulos S, Karatzas P, Katsaros M, Moschovis D, Orfanoudaki E, Livieratos A, Petrikkou E, Mantzaris GJ. **Effect of golimumab on health-related quality of life, other patient-reported outcomes and healthcare resource utilization in patients with moderate-to-severe ulcerative colitis: a real-world multicenter, noninterventional, observational study in Greece.** *Eur J Gastroenterol Hepatol.* 2021 May 21. doi: 10.1097/MEG.0000000000002182. Epub ahead of print. PMID: 34034278.

Validation

Regnault A, et al, **Validation of the Treatment Satisfaction Questionnaire for Medication in patients with cystic fibrosis,** *J Cyst Fibros* (2012).

de Vries ST, Haaijer-Ruskamp FM, de Zeeuw D, Denig P. **Construct and concurrent validity of a patient-reported adverse drug event questionnaire: a cross-sectional study.** *Health Qual Life Outcomes.* 2014 Aug 13;12:103. doi: 10.1186/s12955-014-0103-6. PMID: 25115618; PMCID: PMC4243939.



Muntéis Olivas E, Navarro Mascarell G, Meca Lallana J, Maestre Martínez A, Pérez Sempere Á, Gracia Gil J, Pato Pato A. **Cultural adaptation and validation of a peninsular Spanish version of the MSTCQ® (Multiple Sclerosis Treatment Concerns Questionnaire)**. *Neurologia*. 2017 Jan-Feb;32(1):29-39. English, Spanish. doi: 10.1016/j.nrl.2014.12.011. Epub 2015 Feb 16. PMID: 25697827.

Nair MK, Rajaraman V, Chacko D, Russell S, George B, Sumaraj L, Russell PS. **Comparison of the Diagnostic Accuracy and Validity of a Short Version of Teen Screen Questionnaire-Mental Health (TSQ -M-Short) for Use in Community**. *Indian J Psychol Med*. 2015 Apr-Jun;37(2):201-4. doi: 10.4103/0253-7176.155621. PMID: 25969607; PMCID: PMC4418254.

Nair M, Chacko D, Rajaraman V, George B, Samraj L, Russell PS. **The diagnostic accuracy and validity of the teen screen questionnaire-mental health for clinical and epidemiological studies in primary-care settings**. *Indian J Psychol Med*. 2014 Apr;36(2):187-91. doi: 10.4103/0253-7176.130991. PMID: 24860223; PMCID: PMC4031590.

Atkinson MJ, Kumar R, Cappelleri JC, Hass SL. **Hierarchical construct validity of the treatment satisfaction questionnaire for medication (TSQM version II) among outpatient pharmacy consumers**. *Value Health*. 2005 Nov-Dec;8 Suppl 1:S9-S24. doi: 10.1111/j.1524-4733.2005.00066.x. PMID: 16336491.

Shilbayeh SAR, Ibrahim AA. **The anti-clot treatment scale (ACTS): validation of the translated Arabic version among patients undergoing warfarin therapy in Saudi Arabia**. *Health Qual Life Outcomes*. 2020 Jul 6;18(1):215. doi: 10.1186/s12955-020-01471-4. PMID: 32631346; PMCID: PMC7339378.

gabapentin

Shilbayeh SAR, Alyahya SA, Alshammari NH, Almutairi WA, Shaheen E. **Treatment Satisfaction Questionnaire for Medication: Validation of the Translated Arabic Version among Patients Undergoing Warfarin Therapy in Saudi Arabia**. *Value Health Reg Issues*. 2018 Sep;16:14-21. doi: 10.1016/j.vhri.2018.01.007. Epub 2018 Apr 5. PMID: 29626737.

Shilbayeh SAR, Ismail SAER. **Translation, Pilot Psychometric Validation, and Comparative Performance of the Arabic Version of the Anti-Clot Treatment Scale (ACTS)**. *J Pharm Bioallied Sci*. 2021 Jan-Mar;13(1):61-68. doi: 10.4103/jpbs.JPBS_395_20. Epub 2020 Dec 16. PMID: 34084049; PMCID: PMC8142906.

Ruiz MA, Pardo A, Rejas J, Soto J, Villasante F, Aranguren JL. **Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q)**. *Value Health*. 2008 Sep-Oct;11(5):913-26. doi: 10.1111/j.1524-4733.2008.00323.x. Epub 2008 May 20. PMID: 18494753.

Hudgens S, Spalding J, Chaudhari P. **Validation of a Patient-reported Outcome (PRO) Measure and a Clinician-reported Outcome (CRO) Measure to Assess Satisfaction with Pharmacologic Stress Agents for Single-photon Emission Computed Tomography (SPECT) Myocardial Perfusion Imaging (MPI)**. *Clin Ther*. 2016 May;38(5):1141-50. doi: 10.1016/j.clinthera.2016.02.024. Epub 2016 Mar 15. PMID: 26992664.

Other

Gosia Sylwestrzak, MA; Jinan Liu, PhD; Judith J. Stephenson, SM; Alexander P. Ruggieri, MD, MHS; Andrea DeVries, PhD. **Considering Patient Preferences When Selecting Anti-Tumor Necrosis Factor Therapeutic Options**. *Am Health Drug Benefits*. 2014;7(2):71-81.

Acheson LS, Ezard N, Lintzeris N, Dunlop A, Brett J, Rodgers C, Gill A, Christmass M, McKetin R, Farrell M, Shoptaw S, Siefried KJ. **Lisdexamfetamine for the treatment of acute methamphetamine withdrawal: A pilot feasibility and safety trial**. *Drug Alcohol Depend*. 2022 Nov 7;241:109692. doi: 10.1016/j.drugalcdep.2022.109692. Epub ahead of print. PMID: 36399936.

Uchiyama K, Morimoto K, Washida N, Kusahana E, Nakayama T, Itoh T, Kasai T, Wakino S, Itoh H. **Effects of a remote patient monitoring system for patients on automated peritoneal dialysis: a randomized crossover controlled trial**. *Int Urol Nephrol*. 2022 Oct;54(10):2673-2681. doi: 10.1007/s11255-022-03178-5. Epub 2022 Apr 1. PMID: 35362819; PMCID: PMC8972739.



Gantenbein AR, Agosti R, Kamm CP, Landmann G, Meier N, Merki-Feld GS, Petersen JA, Pohl H, Rylvlin P, Schankin CJ, Viceic D, Zecca C, Schäfer E, Meyer I, Arzt ME. **Swiss Quality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results.** *J Headache Pain.* 2022 Nov 18;23(1):142. doi: 10.1186/s10194-022-01515-8. PMID: 36401172; PMCID: PMC9673191.

Markman JD, Schnitzer TJ, Perrot S, Beydoun SR, Ohtori S, Viktrup L, Yang R, Bramson C, West CR, Verburg KM. **Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.** *Pain Ther.* 2022 Dec;11(4):1267-1285. doi: 10.1007/s40122-022-00424-7. Epub 2022 Aug 13. PMID: 35962939.

Paulson S, Ray D, Aranha S, Scales A, Wang Y, Liu E. **Lanreotide Depot to Treat Gastroenteropancreatic Neuroendocrine Tumors in a US Community Oncology Setting: A Prospective, Observational Study.** *Oncol Ther.* 2022 Dec;10(2):463-479. doi: 10.1007/s40487-022-00208-1. Epub 2022 Sep 22. PMID: 36136274; PMCID: PMC9681944.

Meng TC, Szaflarski JP, Chen L, Brunnert M, Campos R, Van Ess P, Pullman WE, Fakhoury T. **Psychosocial outcomes of repeated treatment of seizure clusters with midazolam nasal spray: Results of a phase 3, open-label extension trial.** *Epilepsy Behav.* 2022 Nov 18;138:108989. doi: 10.1016/j.yebeh.2022.108989. Epub ahead of print. PMID: 36410152.

John MP 2nd, Streufert BD, Downes K, Chase CB, Mir HR. **A Prospective Randomized Controlled Trial Comparing Enoxaparin & Rivaroxaban for Venous Thromboembolism Prophylaxis in Orthopaedic Trauma.** *J Orthop Trauma.* 2022 Dec 1;36(12):615-622. doi: 10.1097/BOT.0000000000002454. PMID: 36399673.

Lee SH, Kim YG, Lee SG, Lee SH, Kim YJ, Jeon JY, Jo JY, Yoo HJ, Lee J, Kim TH. **Treatment pattern, satisfaction, and productivity loss of patients with ankylosing spondylitis treated with tumor necrosis factor inhibitors in Korea: A multicenter cross-sectional observational study.** *Int J Rheum Dis.* 2022 May;25(5):523-531. doi: 10.1111/1756-185X.14304. Epub 2022 Feb 20. PMID: 35187866.

Hammad M, Bakry H. **Satisfaction and Adherence to Biological Treatment in Patients with Rheumatic Diseases.** *Curr Rheumatol Rev.* 2021 Dec 30. doi: 10.2174/1573397118666211230101451. Epub ahead of print. PMID: 34967297.

López-Bravo A, Oliveros-Cid A, Sevillano-Orte L. **Treatment satisfaction with calcitonin gene-related peptide monoclonal antibodies as a new patient-reported outcome measure: A real-life experience in migraine.** *Acta Neurol Scand.* 2022 Jun;145(6):669-675. doi: 10.1111/ane.13599. Epub 2022 Mar 3. PMID: 35243611.

Colombo D, Frassi M, Mariano GP, Fusaro E, Lomater C, Medico PD, Iannone F, Foti R, Limonta M, Marchesoni A, Raffener B, Viapiana O, Di Carlo M, Grembiale RD, Guggino G, Faggioli P, Tirri E, Perricone R, Puttini PCS, Vita S, Conti F, Rizzoli S, Roncari B, Fiocchi M, Orsenigo R, Zagni E. **The CHRONOS Real-World Evidence of Biologic Treatments in Psoriatic Arthritis in Italy: A Post Hoc Gender Analysis.** *Womens Health Rep (New Rochelle).* 2022 Feb 2;3(1):162-171. doi: 10.1089/whr.2021.0063. PMID: 35262053; PMCID: PMC8896165.

Abedini R, Abdshah A, Ghandi N, Janatalipour A, Torabi S, Nasimi M. **Treatment satisfaction and response in patients with severe alopecia areata under treatment with diphenylcyclopropenone.** *Health Sci Rep.* 2022 Apr 26;5(3):e602. doi: 10.1002/hsr2.602. PMID: 35509377; PMCID: PMC9059174.

Uchiyama K, Morimoto K, Washida N, Kusahana E, Nakayama T, Itoh T, Kasai T, Wakino S, Itoh H. **Effects of a remote patient monitoring system for patients on automated peritoneal dialysis: a randomized crossover controlled trial.** *Int Urol Nephrol.* 2022 Apr 1:1-9. doi: 10.1007/s11255-022-03178-5. Epub ahead of print. PMID: 35362819; PMCID: PMC8972739.

Saeedi R, Sultana A, Rahman K, Belal Bin Heyat M, Kamal MA, Ishawu M. **Efficacy of Acacia nilotica Linn. Pod's Sitz Bath plus Vaginal Pessary in Syndromic Management of Abnormal Vaginal Discharge: A Randomized Controlled Trial.** *Evid Based Complement Alternat Med.* 2022 May 25;2022:5769555. doi: 10.1155/2022/5769555. PMID: 35664940; PMCID: PMC9159874.

Rejas J, Ruiz MA, Pardo A, Soto J. **Minimally important difference of the Treatment Satisfaction with Medicines Questionnaire (SATMED-Q).** *BMC Med Res Methodol.* 2011 Oct 20;11:142. doi: 10.1186/1471-2288-11-142. PMID: 22014277; PMCID: PMC3241617.



Löffler C, Drewelow E, Paschka SD, Frankenstein M, Eger J, Jatsch L, Reisinger EC, Hallauer JF, Drewelow B, Heidorn K, Schröder H, Wollny A, Kundt G, Schmidt C, Altiner A. **Optimizing polypharmacy among elderly hospital patients with chronic diseases--study protocol of the cluster randomized controlled POLITE-RCT trial.** *Implement Sci.* 2014 Oct 6;9:151. doi: 10.1186/s13012-014-0151-7. PMID: 25287853; PMCID: PMC4192341.

Lin HY, Cheng TT, Wang JH, Lee CS, Chen MH, Lei V, Lac C, Gammaitoni AR, Smugar SS, Chen WJ. **Etoricoxib improves pain, function and quality of life: results of a real-world effectiveness trial.** *Int J Rheum Dis.* 2010 May;13(2):144-50. doi: 10.1111/j.1756-185X.2010.01468.x. PMID: 20536599.

Hanson KA, Agashivala N, Stringer SM, Balantac Z, Brandes DW. **A cross-sectional survey of patient satisfaction and subjective experiences of treatment with fingolimod.** *Patient Prefer Adherence.* 2013 Apr 16;7:309-18. doi: 10.2147/PPA.S41992. PMID: 23620662; PMCID: PMC3633540.

Fallu A, Dabouz F, Furtado M, Anand L, Katzman MA. **A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA®) and generic novo-methylphenidate ER-C (NOVO-generic).** *Ther Adv Psychopharmacol.* 2016 Aug;6(4):237-51. doi: 10.1177/2045125316643674. Epub 2016 May 1. PMID: 27536342; PMCID: PMC4971598.

Dash A. **Assessment of Patient Satisfaction with Generic Medication in Emerging Economy Using the Treatment Satisfaction Questionnaire for Medication.** *J Patient Exp.* 2021 Nov 18;8:23743735211060791. doi: 10.1177/23743735211060791. PMID: 34820510; PMCID: PMC8606963.

Markman JD, Schnitzer TJ, Perrot S, Beydoun SR, Ohtori S, Viktrup L, Yang R, Bramson C, West CR, Verburg KM. **Clinical Meaningfulness of Response to Tanezumab in Patients with Chronic Low Back Pain: Analysis From a 56-Week, Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial.** *Pain Ther.* 2022 Aug 13. doi: 10.1007/s40122-022-00424-7. Epub ahead of print. PMID: 35962939.

Elterman DS, Zorn KC, Bhojani N, Chughtai B. **Efficacy and safety of methoxyflurane (Pentrox) for pain control during water vapor thermal therapy (Rezum) for benign prostatic enlargement.** *Can J Urol.* 2022 Dec;29(6):11355-11360. PMID: 36495576.

Mallick R, Solomon G, Bassett P, Zhang X, Patel P, Lepeshkina O. **Immunoglobulin replacement therapy in patients with immunodeficiencies: impact of infusion method on patient-reported outcomes.** *Allergy Asthma Clin Immunol.* 2022 Dec 24;18(1):110. doi: 10.1186/s13223-022-00746-3. PMID: 36566213; PMCID: PMC9789520.

Manyazewal T, Woldeamanuel Y, Getinet T, Hoover A, Bobosha K, Fuad O, Getahun B, Fekadu A, Holland DP, Marconi VC. **Patient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial.** *EClinicalMedicine.* 2023 Jan 17;56:101820. doi: 10.1016/j.eclinm.2022.101820. PMID: 36684395; PMCID: PMC9853306.